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High density lipoprotein (HDL), low density lipoprotein (LDL), and very low
density lipoprotein (VLDL) are lipoproteins previously shown to bind many basic and
neutral hydrophobic drugs in serum. These interactions impact the distribution, delivery,
metabolism, and excretion of drugs and are important in determining drug activity,
pharmacokinetics, and toxicity in the human body. Information about drug-lipoprotein
interactions and the strength of these interactions can be useful in determining the
distribution of drugs following administration.
The research presented in this dissertation uses high performance affinity
chromatography (HPAC) and packed columns to study binding of the drug propranolol to
immobilized lipoproteins such as HDL, LDL, and VLDL. Through these studies, two
types of interactions were identified between the lipoproteins and propranolol and
verapamil. The first interaction has a relatively high affinity and likely involves binding
of the drug by surface apolipoproteins. This high-affinity saturable interaction was
stereoselective for LDL. HDL and VLDL did not exhibit stereoselectivity. The second

type of interaction observed in each lipoprotein had a lower affinity involved partitioning
of the drug into the non-polar core of lipoproteins.
Additional work analyzing the theory and experimental conditions needed for the
detection of multiple binding mechanisms in HPAC columns when using frontal analysis
is also presented. This work focuses on the evaluation of binding models that
incorporated both a saturable type of binding and a non-saturable interaction. These
evaluations make it possible to determine the experimental conditions that would be
required for detection of this type of multi-mode interaction.
These studies demonstrate that HPAC is a useful tool in characterizing mixedmode interactions, as can occur with complex particles like lipoproteins. The affinity
columns containing immobilized lipoproteins allowed these studies to be conducted using
the same column for hundreds of experiments with short analysis times. The combined
result of these advantages was the ability to quickly obtain precise data over a variety of
drug concentrations. The results of these experiments indicate that similar columns
prepared with other lipoproteins or biological membranes can be used in similar HPAC
binding studies.
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CHAPTER ONE
INTRODUCTION

Portions of this chapter have previously appeared in M.R. Sobansky and D.S. Hage,
“Analysis of Drug Interactions with Lipoproteins by High-Performance Affinity
Chromatography", In: Advances in Medicine and Biology, Vol. 53, L.V. Berhardt (ed.),
Nova Science Publishers, 2012, Chapter 9.

Drug interactions with serum proteins and other binding agents within the blood
play an important role in determining the apparent activities of many pharmaceutical
agents that have entered the circulatory system. For example, the distribution and
pharmacokinetics of numerous drugs within the body is impacted by the binding of these
agents [1-3]. Direct and/or indirect competition between a drug and another agent (e.g.,
another drug or endogenous compound) for the same binding sites on a serum agent may
also significantly impact drug-drug or drug-solute interactions [4-8]. Furthermore, the
solubility of hydrophobic compounds may be enhanced by the binding of solutes in the
blood [9].
The ability of a pharmaceutical agent to illicit a response is significantly impacted
by these typically reversible binding mechanisms. This is due to the fact that only an
unbound drug molecule contained within the blood is able to reach its receptor and target
tissue, to be metabolized by the liver, or to be excreted by the kidneys from the
circulatory system. A drug bound to proteins or other agents is generally not available
for these processes or to illicit a response [10]. The effects of drugs binding to such
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agents in the circulatory system can be illustrated by the general model that is given in
Figure 1-1. The interactions between drugs and serum agents are often significant, as
demonstrated by the fact that 43% of the 1500 most frequently prescribed drugs have
90% or greater binding to serum proteins and other agents [11]. The frequent and
extensive occurrence of drug and serum agent interactions mandates that the evaluation
of this binding be an important part of the adsorption, distribution, metabolism, and
excretion data that are required by the various health authorities for the approval a new
pharmaceutical compound [10].
Lipoproteins such as high-density lipoprotein (HDL), low-density lipoprotein
(LDL), and very low-density lipoproteins (VLDL) are a group of binding agents known
to interact with several basic and neutral hydrophobic drugs and other solutes in blood
[12-23]. Propranolol and verapamil are two examples of drugs that are known to engage
in these types of interactions with lipoproteins [2,12-19]. The binding of such drugs with
various lipoproteins was the focus of the research in this dissertation. The interactions of
such drugs with LDL, VLDL, and HDL have been analyzed previously by means of
equilibrium dialysis and capillary electrophoresis (CE) carried out in a frontal analysis
mode [20-23].
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Figure 1-1.

General model for drug interactions with proteins and other binding agents
in blood and the relationship of this binding to the ability of a drug to
reach its target or to be acted on by the liver and kidneys. This figure is
reproduced with permission from Ref. [54].
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Equilibrium dialysis is often the reference method for the evaluation of drug
interactions with proteins or other macromolecules. This method is inexpensive to
perform but has several drawbacks. The drawbacks of equilibrium dialysis include its
requirement for a large amount of binding agent, the time consuming nature of the test,
and its susceptibility to errors arising from leakage of the bound drug fraction through the
membrane and/or adsorption of the drug onto the membrane [21]. CE/frontal analysis
does not require the use of a membrane and overcomes many of the disadvantages
associated with equilibrium dialysis. In addition, CE/frontal analysis provides a
relatively quick method that requires relatively small amounts of samples and binding
agents [21]. The primary handicap of CE in the evaluation drug interactions is the higher
limits of detection that arise when compared to other methods that utilize bench top
spectrometers or HPLC systems [24,25].
High-performance affinity chromatography (HPAC) is an alternate technique to
equilibrium dialysis and CE/frontal analysis for evaluating drug - protein interactions
[3,7-9]. HPAC utilizes high-performance liquid chromatography columns that contain an
immobilized binding agent (e.g., HDL, LDL, or VLDL) to which a solution or sample of
the drug of interest is applied [26-28]. Based upon past studies, HPAC has shown to be
a valuable tool for studying drug interactions with serum proteins as information related
to equilibrium constants and the stoichiometry of the interactions occurring within the
column can be determined [3,7-9]. As will be demonstrated in this dissertation, the speed
and ease of automation make HPAC advantageous when compared to equilibrium
dialysis. HPAC provides superior precision when compared to equilibrium dialysis and
CE due to the ability of HPAC to use the same preparation of binding agent for a large
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number of studies. This feature reduces batch-to-batch and run-to-run variations.
Furthermore, HPAC can be interfaced with a variety of HPLC detectors, making it
possible to use this method with a wide range of solutes while obtaining low detection
limits [10].
HPAC has been employed in many previous studies that have examined drug
interactions with serum proteins, such as human serum albumin (HSA) and α1-acid
glycoprotein (AGP) [10]. This technique has also been extended to work with binding
agents, such as HDL, LDL, and VLDL in this research [24,25,29]. This chapter describes
the basic principles of HPAC and the properties of the lipoproteins that were evaluated,
as well as providing an overview of the drugs that were used as model compounds as a
means to determine if HPAC was a suitable method for obtaining information regarding
drug-lipoprotein interactions. Subsequent chapters within this thesis provide specific
details on the experiments that were utilized to determine the nature and strength of druglipoprotein interactions, along with the results and significance of these experiments, and
potential topics of interest for future work.

Properties of Lipoproteins
Lipoproteins such as HDL, LDL, and VLDL are soluble complexes of lipids and
proteins (i.e., apolipoproteins) arranged into a macromolecular structure. The general
structure of a lipoprotein is depicted in Figure 1-2. A primary function of these
complexes is to transport hydrophobic compounds such as cholesterols, triacylglycerides
(triglycerides) and lipids throughout the body [12-14]. Lipoproteins are also known to
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interact with and transport several types of basic or neutral and hydrophobic drugs in the
bloodstream [12-19,33].
As shown in Figure 1-2, triacylglycerol and cholesterol esters form the non-polar
lipid core of a lipoprotein. This core is surrounded by a monolayer of phospholipids and
apolipoprotein(s) covering the surface of lipoprotein. The phospholipids and
apolipoprotein(s) in this layer are oriented to allow solubilization of the complex.
Individual phospholipids are arranged so that the phosphate-containing head of the
molecule is on the outer face of the complex while the lipid tail is positioned towards the
non-polar core of the apolipoprotein [12,13].
Human lipoproteins have historically been divided into five primary classes based
upon density. These five categories are, in order of increasing density, chylomicrons
(CM), very low density lipoproteins (VLDL), low density lipoproteins (LDL),
intermediate density lipoproteins (IDL) and high density lipoproteins (HDL) [12,14-18].
The properties that differentiate these lipoproteins are summarized in Table 1-1.
In addition to their structural differences, lipoproteins may be divided by the
functional role that they serve within the body. Chylomicrons are typically formed
following absorption of triacylglycerides and cholesterol within the intestinal tract.
Chylomicrons are incorporated into the bloodstream, where free fatty acids are removed
by lipoprotein lipase and delivered to various tissues. Chylomicron remnants are then
delivered to the liver where they are repackaged as VLDL. VLDL transports endogenous
triacylglycerides, phospholipids, cholesterol and cholesteryl esters throughout the body.
Lipoprotein lipase removes additional triacylglycerides from VLDL, leaving IDL (i.e.,
VLDL remnants). IDL is then converted to LDL. LDL carries cholesterol esters formed

8
in the liver to muscles and other extrahepatic tissues. A process known as reverse
cholesterol transport utilizes HDL to remove excess cholesterol from peripheral tissues.
The removed cholesterol is delivered to the liver for excretion and recycling [12,13]. The
process of lipoprotein transport is depicted in Figure 1-3.
The exact lipoprotein composition and distribution in an individual is dependent
on a variety of factors, including sex, age, race, metabolic condition, and disease state
[12,13,16]. The typical lipoprotein levels in a healthy fasting adult male are
approximately 280 mg/dL HDL, 410 mg/dL LDL, and 150 mg/dL VLDL [13].
Chylomicrons are only present immediately following a meal; therefore, typical fasting
levels for this type of lipoprotein are 0 mg/dL [13]. Disruptions in the type and/or
concentration of these lipoproteins may result in detrimental health effects such increased
risk of cardiovascular disease [12-18].
The transport and distribution of hydrophobic or non-polar compounds of
endogenous or exogenous origin is also facilitated by the presence of lipoproteins
[12,14,18]. Examples of substances that are transported through interactions with
lipoproteins include vitamin E and drugs such as amitriptyline, chlorpromazine,
desipramine, imipramine, propranolol, verapamil, quinidine and nilvadipine
[5,21,30,31,35-39].
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Figure 1-2.

Structure of a lipoprotein. This figure is reproduced with permission from
Ref. [25].
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Table 1-1

Typical Properties of Human Lipoproteins

Lipoprotein

Density
(g/mL)

Diameter
(nm)

Associated
Apolipoproteins

HDL

1.0631.210

5-15

LDL

1.0191.063

IDL

Composition (% dry weight)
Protein

Cholesterol

Phospholipid

Triacylglyceride

A-I, A-II, A-IV, C-I,
C-II, C-III, D, E

55

17

24

4

18-28

B-100

23

45

20

10

1.0061.019

25-50

B-100, C-I, C-II, CIII, E

18

29

22

31

VLDL

0.951.006

30-80

B-100, C-I, C-II, CIII, E

10

19

18

50

Chylomicron

<0.95

100-500

A-I, A-II, A-IV, B-48,
C-I, C-II, C-III, E

2

4

9

85

Major associated apolipoproteins are shown in bold.
This table is adapted from Ref. [34].
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Figure 1-3.

The process of lipoprotein transport [34].

Reverse cholesterol
transport

Intestine
Liver

HDL
LDL
Chylomicron
remnants
VLDL

Extrahepatic
tissues

IDL

Chylomicrons

Capillary

Free fatty acids to
Mammary, muscle, or adipose tissue
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General properties of model drugs
Two model drugs were used in this work for the evaluation of drug-lipoprotein
interactions by HPAC. The first model drug was propranolol (see Figure 1-4). This drug
is a basic, chiral drug that is known to interact with several serum proteins and
lipoproteins, including HSA, AGP, HDL, LDL, and VLDL [20-23]. Propranolol is a
non-selective beta adrenergic blocking agent that is used in the treatment of several
disorders, such as hypertension, angina, and arrhythmia [40-42]. Propranolol is basic and
relatively non-polar, as indicated by its pKa of 9.45 and its log P value of 3.00, allowing a
number of interactions with lipoproteins feasible for this drug [40,43,44]. These
interactions may include interactions with specific binding regions, interactions with
surface phospholipids, or partition-based interactions with the non-polar core of a
lipoprotein [12-19,33].
The second model drug that was evaluated was verapamil (see Figure 1-5).
Verapamil is a calcium channel blocker used to treat hypertension, angina pectoris, and
cardiac arrhythmia [22,45]. This drug is basic (pKa of 8.75) and chiral, with the Senantiomer showing higher pharmacological activity than the R-enantiomer [22,46].
Verapamil is also relatively non-polar, with a log P value of 3.79 [47]. These properties
make interactions of this drug with lipoproteins possible at specific binding regions,
surface phospholipids, or partition interactions with the non-polar core of the lipoprotein.
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Figure 1-4.

Structure of propranolol. The chiral center is indicated with an asterisk (*).
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Figure 1-5.

Structure of verapamil. The chiral center is indicated with an asterisk (*).
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General Principles of High-Performance Affinity Chromatography
Affinity chromatography is a liquid chromatographic technique that utilizes
biological agents as a stationary phase for the purification or analysis of a target
compound dissolved in a sample solution [26-28]. Solute retention in affinity
chromatography is based on the specific and reversible interactions that are commonly
found in biological systems. These types of interactions are exploited in affinity
chromatography by immobilizing one of a pair of interacting molecules on a solid
support within a liquid chromatographic system. The immobilized molecule is referred
to as the affinity ligand and serves as the stationary phase in the chromatographic system
[10]. Examples of interactions that are commonly evaluated using affinity
chromatography include the binding of a substrate by an enzyme, and the binding of an
antigen by an antibody.
High performance affinity chromatography (HPAC) is a type of affinity
chromatography that utilizes HPLC systems and solid supports that consist of small, rigid
particles. These supports are typically comprised of materials such as silica or glass,
azalactone beads, hydroxylated polystyrene media or monolith columns [10,26,27,48-51].
These materials are used due to their ability to withstand the moderate-to-high flow rates
and pressures that can be present in an HPLC system. Furthermore, these supports offer
the enhanced mass transfer properties needed in chromatographic separations. While
HPLC instrumentation increases the cost of performing HPAC measurements compared
to traditional or low pressure affinity methods, the improved speed and precision of
HPAC make it preferable for analytical applications [10].
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Another potential advantage of HPAC compared to other methods for determining
drug interactions with serum binding agents is that the same ligand preparation can be
used for multiple experiments. Thus, only a small amount of protein is required to
conduct a large number of studies, which provides optimum precision by minimizing runto-run variations [52]. Additional benefits of HPAC its ease of automation and the
relatively short time periods needed for conducting binding studies. This is exemplified
in the HPAC studies utilizing lipoproteins described in this research, where the typical
run time was 5-10 min per analysis [24,25,29]. The analysis time is significantly less
than the time needed for comparable studies using equilibrium dialysis or ultrafiltration
[52]. Furthermore, the HPAC column and immobilized ligand are continuously washed
with fresh mobile phase, which minimizes the effects on drug interactions by residual
contaminants that may have been present in the original preparation of the binding agent
[52]. Finally, the use of HPLC detectors provides low limits of detection and allows for a
variety of compounds to be evaluated over a broad range of concentrations in HPAC
[10,24]. These characteristics make HPAC a valuable tool for characterizing the
interactions that occur between drugs and proteins, lipoproteins, or other binding agents
in blood or serum. The realization of these benefits in this research is described in the
subsequent chapters through the results for the HDL, LDL, and VLDL binding studies.
Experiments based on high performance affinity chromatography studies and used
to examine solute-ligand interactions are typically carried out by one of two
methodologies, i.e., zonal elution or frontal analysis. In each method, the immobilized
ligand is the binding agent of interest and analyte application onto the column is made in
the presence of only buffer or buffer containing a modifier/competing agent. At the
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completion of a run, the analyte’s elution time or volume are determined as a means to
gain information regarding the interactions occurring between the affinity ligand and the
analyte. In addition, the equilibrium constants and number of binding sites involved in
the binding process can be determined. The presence of competing agents in the mobile
phase allows one to obtain data regarding how these agents’ impact analyte-ligand
interactions. Additionally, information on the rates of these binding processes may be
acquired through examination of the analyte elution profile. These approaches have been
used previously to examine the binding of numerous drugs to various proteins and
transport agents in blood [9,10]. The focus of this research was the use of HPAC to study
the binding mechanism, strength of binding, and stoichiometry for drug interactions with
HDL, LDL, and VLDL.
The development of a stationary phase for the analysis of solute-ligand
interactions using HPAC requires investigating the degree to which interactions with the
immobilized agent mimic those by the same agent in its native form. Typically, this
evaluation is performed by comparing the binding parameters for a model drug or solute
with the immobilized agent and when using HPAC versus those obtained for the same
system in its native state. Native state results are often obtained through equilibrium
dialysis, ultrafiltration, or other solution-based reference methods [9,10]. Previous work
with columns containing immobilized proteins such, as HSA and AGP, have routinely
demonstrated that binding parameters determined using HPAC agree with values
obtained using soluble HSA or AGP in drug binding studies [10]. Similar studies that
have been carried out with HDL, LDL, and VLDL columns, as described in this
dissertation, have led to the same conclusions [24,25,29].
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Preparation of lipoprotein supports for HPAC
The effective evaluation of drug binding with a ligand by HPAC begins with the
immobilization of the ligand to a support. Porous silica is one support material that is
commonly used in HPAC, including the lipoprotein studies that were conducted in this
dissertation. Porous silica was selected as a support material over other common
supports, such as polystyrene or carbohydrate-based resins, due to silica’s mechanical
stability, chemical inertness, and long term stability in the presence of a physiological
buffer (e.g., the pH 7.4, 0.067 M potassium phosphate buffer that was used as a mobile
phase in this work) [24,25,29]. Prior to covalent immobilization of an affinity ligand to
the surface of a porous silica support, surface silanol groups are modified with an
organosilane containing functional groups that can later be used or modified for the
immobilization process.
For these studies, the surface of the silica support was modified to a diol-bonded
form prior to the immobilization of the ligands of interest (i.e., HDL, LDL, or VLDL).
This modification process is shown in Step 1 of Figure 1-6. Surface modification of the
silica reduces the presence of charged silanol groups, which could lead to non-specific
binding of biological agents, and provides sites that can later be modified for the covalent
immobilization of the desired lipoprotein [24,25,29].
Lipoproteins were immobilized on silica supports via covalent bonding to provide
a stable linkage and robust affinity column [50]. The immobilization of each ligand was
accomplished by using a modified form of the Schiff base method, or reductive
animation, to attach lipoproteins to the diol-bonded silica [24,25,29]. This process was
initiated with the periodic acid-based oxidation of the diol-bonded silica to create an
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aldehyde-activated support (see Step 2 in Figure 1-6) [50]. The aldehydes on the support
were then reacted with primary amine groups on the apolipoproteins of HDL, LDL, or
VLDL, resulting in nucleophilic addition to form an imine (Step 3). This reaction was
buffered at pH 6.0 to maintain selectivity for amines with low pKa values, such as the Nterminal regions of proteins [24,25,29]. Due to the reversible nature of imine formation,
the resulting imines were reduced with sodium cyanoborohydride to generate a stable
secondary amine (Step 4) [53]. Sodium borohydride was later added to reduce any
remaining aldehydes on the support to alcohols. This helped minimize non-specific
binding that may occur between sample components with these types of functional
groups [53].

Zonal elution studies of drug interactions with lipoproteins
Zonal elution is the most popular method used in the analysis of solute-ligand
binding in affinity chromatography. This elution method is performed using the same
techniques as most typical analytical applications of liquid chromatography. For
example, a narrow plug of solute is injected onto a column containing an immobilized
ligand, while the elution time or volume of the solute is monitored [9-10,52]. Zonal
elution has been utilized in past studies to examine the extent of drug binding by agents
such as serum albumins (including HSA) and AGP [10].
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Figure 1-6.

Lipoprotein immobilization to silica by the Schiff base method. This
Figure is reproduced with permission from Ref. [54].
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A typical system for performing zonal elution studies in HPAC consists of five
primary components. The first component is a high pressure pump that is capable of
delivering a constant flow of mobile phase through the packed column. A narrow plug of
solute is injected into the mobile phase by using a closed injection loop or autoinjector.
The dissolved analyte is then carried by the mobile phase to the HPAC column. The
HPAC column is the source of the observed interactions between the injected analyte and
the immobilized ligand. The elution profile for the analyte is monitored via an online
detector as the solute emerges from the column. Finally, a computer or other recording
device is used to obtain the detector’s response as a function of the elution time or
applied mobile phase volume, thus providing the final chromatogram that is utilized for
analysis. A typical setup for a zonal elution HPAC system is shown in Figure 1-7.
Prior work has employed zonal elution and other ligands to measure the degree
and affinity of solute-ligand binding, to examine changes in binding with variations in the
mobile phase composition (e.g., pH, ionic strength, or polarity) or column temperature,
and to see how alterations in solute or ligand structure may affect these interactions [10].
The fact that the retention of an injected analyte is a direct measure of the number of
binding sites within a column and the strength with which the analyte is binding to the
immobilized ligand is exploited in these studies. These relationships are described by
Eqs. (1)-(2).

𝑘 = [(𝑛1 𝐾𝑎1 + ⋯ + 𝑛𝑛 𝐾𝑎𝑛 )𝑚𝐿 ]/𝑉𝑀

(1)

𝑘 = [𝑛𝐾𝑎 𝑚𝐿 ]/𝑉𝑀

(2)
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Figure 1-7.

Typical system for performing zonal elution studies.
reproduced with permission from Ref. [54].

This Figure is
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These equations demonstrate that the retention factor (k) for an analyte on an
affinity column is related to the number of binding sites in the column and the association
equilibrium constants for the analyte at each of these sites [9,10,52]. The association
equilibrium constants for the analyte at its individual binding sites on the ligand are
defined as terms Ka1 through Kan in Eq. (1). The stoichiometry for the analyte in each
type of interaction is described in Eq. (1) by the terms n1 through nn. The summation of
the terms n1Ka1 through nnKan in Eq. (1) is the global affinity or global association
equilibrium constant, nKa, as given in Eq. (2) [10]. The term VM (Eqs. (1)-(2)) refers to
the void volume of the column. Finally, mL is the total moles of binding sites for the
analyte in the column [9-10,52]. A review of these equations reveals that a change in the
number of binding sites, the distribution of these sites, or the strength of binding at an
individual site can result in a shift of analyte retention on an affinity column. This
concept has been used in the course of experimentation associated with this dissertation
in the evaluation of the stability of HPAC columns containing immobilized lipoproteins.
These studies were executed by monitoring the retention of the model drug propranolol
on columns containing HDL, LDL, or VLDL over time [24,25,29].
R-Propranolol and/or S-propranolol were used in these studies to evaluate column
stability because these drugs are known to bind to HDL, LDL, and VLDL [20]. The
stability of the lipoprotein columns was evaluated by measuring the retention of these
analytes through a series of injections made onto new HPAC columns containing
immobilized HDL, LDL, or VLDL [24,25,29]. The goal of these studies was to
determine when a change in the retention of R- or S-propranolol occurred; this change
indicated that a variation had occurred in the stability of the lipoprotein column. This
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evaluation was used to determine if retention was consistent over a long enough period of
column use, thus enabling more extensive HPAC studies. After confirming that column
stability was sufficient with such columns, similar columns were utilized in more
extensive experiments, such as the measurement of the equilibrium binding constants and
binding stoichiometry between applied drugs and immobilized lipoproteins. Typical
chromatograms that were obtained during these types of evaluations are shown in Figure
1-8. The acceptable period of use for each of the lipoprotein columns was more than
sufficient for the types of drug binding studies that were planned in the next phase of
experiments [24,25,29].
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Figure 1-8.

Typical chromatograms obtained during lipoprotein column stability
studies. This depicted study was carried out using R-propranolol and a 2.1
× 100 mm i.d. column containing immobilized LDL. The column was
held at 37 °C and contained a mobile phase of pH 7.4, 0.067 M phosphate
buffer flowing at 1.0 mL/min. The dashed vertical line depicts the central
moment of the peak for R-propranolol at the beginning of this experiment.
The volumes indicate the total volume buffer applied at the time the
measurement was made. This figure is reproduced with permission from
Ref. [25].

Absorbance (225 nm)
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Frontal analysis studies of drug interactions with lipoproteins
A second method commonly used in the execution of HPAC binding studies is
frontal analysis. Frontal analysis is performed by continuously applying a solution
containing a known concentration of an analyte at a fixed flow rate to a column
containing an immobilized ligand; this is analogous to a titration of the ligand binding
sites that are available within the column for the analyte [9,10,52]. This technique has
been used previously to quantitatively determine the amount of ligand in a column and
the binding affinity of numerous solutes and serum proteins, including HSA and AGP
[10]. Frontal analysis was employed throughout this dissertation to evaluate the HDL,
LDL, and VLDL columns that were prepared and to determine and quantify the types of
interactions these ligands had with an applied drug [24,25,29].
A typical chromatographic system used in performing HPAC in the frontal
analysis mode is similar to that used for zonal elution but with one significant difference.
In frontal analysis, a typical system utilizes at least two high pressure pumps or delivery
lines that are capable of delivering various mobile phase solutions to the system. The
application buffer is applied by one of the pumps or delivery lines, while the second
pump/line delivers a solution containing a known concentration of the desired analyte
dissolved in the application buffer. Typically, the application buffer is a solution
designed to mimic the pH and surroundings of the ligand in its natural environment. In
this dissertation, such work was conducted by using pH 7.4, 0.067 M phosphate buffer as
the application solution to mimic serum conditions. Control of the solution applied to the
HPAC column at any given time is maintained by using a high pressure valve. A third
pump can be used to a pass an elution buffer through the column to release any analyte
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that has been retained; however, this was not necessary for the lipoprotein-drug
interactions monitored in this dissertation. An on-line detector is used to monitor the
elution profile for the analyte, and a computer or recording device is used to collect this
data for analysis. The typical setup for a frontal analysis HPAC system is shown in
Figure 1-9.
The binding capacity and equilibrium binding constants of an affinity column for
an applied analyte are often measured by using frontal analysis studies. Over the course
of a run, the analyte applied to the column by the application buffer results in the
saturation of the fixed binding sites on the ligand, resulting in an increase in the amount
of analyte that elutes from the column. The detector response over the course of the run
generates a breakthrough curve, as illustrated in Figure 1-10. These breakthrough curves
are generated at several concentrations of the analyte and at a known mobile phase
composition and temperature. The volume of the analyte solution, or the moles of
applied analyte, that are required to reach the mean position of this breakthrough curve is
determined by integration of the curve. The mean position of the breakthrough curves
can then be related to the concentration of the applied analyte, the amount of ligand in the
column, and the equilibrium constants for the analyte-ligand interaction if the association
and dissociation kinetics of the analyte-ligand interaction are known or assumed to be
fast relative to the time scale of the experiment [8,9]. This binding information is
obtained by fitting the results of the frontal analysis experiments to expressions that
represent one or more binding models. The models utilized in this dissertation for the
assessment of drug-lipoprotein interactions are summarized in Table 1-2; which will be
discussed further in the next section.
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Figure 1-9.

Typical system for performing frontal analysis. This Figure is reproduced
with permission from Ref. [54].
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Figure 1-10. Typical breakthrough curves obtained during frontal analysis studies with
columns containing immobilized lipoproteins. This particular study was
carried out using a 2.1 × 50 mm i.d. column containing immobilized HDL.
The column was held at 37 °C while various concentrations of Rpropranolol dissolved in pH 7.4, 0.067 M phosphate buffer were applied at
1.0 mL/min. These chromatograms are reproduced with permission from
Ref. [24].
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Various types of information about a solute-ligand interaction can be obtained
from properly designed frontal analysis experiments. These experiments can provide
details regarding the affinity and number of binding sites for a solute on an affinity ligand
and the type of interaction(s) between the solute and ligand (e.g., single site versus multisite binding, and saturable versus non-saturable interactions) [9,10]. Frontal analysis may
also be employed to evaluate the effects of temperature, solvent composition, pH, or the
impact of a competing agent on solute-ligand interactions, [9,10]. The speed and
relatively large amount of information that can be obtained in a frontal analysis
experiment on a HPAC system make this technique advantageous when compared to
solution-based methods, such as equilibrium dialysis, for binding studies [9,10,52].
While HPAC may be operated in either frontal analysis or zonal elution modes, only
frontal analysis is capable of simultaneously providing information on both the number of
binding sites and equilibrium constants for a solute with an immobilized binding agent.
The ability to obtain this information in a single set of experiments has made frontal
analysis the preferred method in many drug-protein binding studies and for highthroughput screening of drug-protein interactions [9,10,52].
A properly designed frontal analysis experiment requires the consideration and
optimization of several factors prior to execution. One such factor is the choice of the
affinity column. The column should be prepared in a way that provides a ligand that is
stable over the course of the study and that mimics the ligand’s behavior in its native
environment [9,10]. The possibility of non-specific binding by the analyte to the support
or other non-ligand components of the column must be minimized as well. This nonspecific binding can be reduced through the proper selection of immobilization
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conditions. Any remaining non-specific binding may be accounted for and corrected by
carrying out equivalent frontal analysis studies on a control column with no immobilized
ligand present [9,10]. Analyte concentrations utilized in frontal analysis experiments
should be selected by considering the expected equilibrium constants for the interaction
and specific analyte properties (i.e., detectability and solubility) [8-10]. Finally, the
approach utilized in determination of the breakthrough times must be considered. The
point that is halfway between the baseline and the plateau can be used to find the
breakthrough time for a symmetrical curve. Determination of the breakthrough time for
an asymmetrical curve can be determined by finding the centroid of the first derivative of
the curve or by determination of the point at which the area below the front portion of the
curve is equal to the area above the latter portion of the curve [10]. This latter method
was used in these studies as a non-symmetrical curve was typically seen for lipoprotein
columns.

Potential models for drug-lipoprotein interactions
The structure of lipoproteins, as described earlier, lends itself to a number of
possible interactions with drugs or other solutes. For example, previous studies have
suggested that such substances may interact with the hydrophobic core or with
phospholipids on the surface of the lipoprotein [21-23]. In addition, it is possible that the
analyte may undergo more specific binding with the specific apolipoproteins that are
incorporated in the lipoprotein particle or that a combination of several types of
interactions may be present [24,25,29]. A depiction of these potential binding
mechanisms is shown in Figure 1-11. Each of these four binding mechanisms was
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considered when analyzing frontal analysis data that were obtained for various drugs with
HPAC columns containing immobilized lipoproteins [24,25,29].
The most basic interaction model evaluated for the drug-lipoprotein binding
studies in this dissertation was one in which the drug interacted with the hydrophobic
core of the lipoprotein or with a large group of non-saturable sites [20,21,24,25]. This
type of interaction is represented in Table 1-2 by the non-saturable, or partition type,
model in Eq. (3). A similar model in which the drug interacts with a single group of
saturable sites, as might occur on the apolipoproteins at the surface of a lipoprotein, was
also considered [24,25,29]. This type of interaction is represented by Eq. (4) in Table 12. The model described by Eq. (5) in Table 1-2 is a mixed-mode model, in which a
combination of saturable sites and a group of non-saturable interactions are present
[24,25,29]. This model is described by Eq. (5) in Table 1. Finally, a model where
multiple, but distinct, site-specific interactions were present was evaluated by using Eq.
(6) in Table 1-2 [24,25,29].
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Figure 1-11. Possible drug-lipoprotein binding mechanisms. This Figure is reproduced
with permission from Ref. [54].
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Table 1-2.

Binding models used with frontal analysis data for drugs on lipoprotein columns

Binding model
Non-saturable interaction
Single group of saturable sites
Saturable sites + non-saturable interaction
Two groups of saturable sites
a

Predicted responsea
mLapp = mL1Ka1[D]
mLapp = (mL1Ka1[D])/(1 + Ka1[D])
mLapp = (mL1Ka1[D])/(1 + Ka1[D]) + mL2Ka2[D]
mLapp = (mL1Ka1[D])/(1+Ka1[D]) + (mL2Ka2[D])/(1+Ka2[D])

(3)
(4)
(5)
(6)

Symbols: mLapp, moles of applied analyte required to reach the mean position of the breakthrough curve; mL1, total moles of active binding site 1; Ka1,

association equilibrium constant for binding of the analyte to the ligand at site 1; [D], concentration of the applied drug; mL2, total moles of active binding
site 2; Ka2, association equilibrium constant for binding of the analyte to the ligand at site 2.
Adapted from Refs. [24,25,29].
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The frontal analysis data obtained with HDL, LDL, and VLDL were evaluated
using these four binding models. The first step in evaluating these binding models was to
prepare a graph of the frontal analysis results that were obtained at a given temperature
by plotting the apparent moles of analyte (mLapp) required to reach the mean position of
the breakthrough curve versus the concentration of applied drug ([D]) used to generate
this result. This plot was then fitted to each of the equations shown in Table 1-2 to
determine the model that resulted in the best description of the experimental results. The
quality of each fit was examined and compared by using the correlation coefficients for
the fits, the overall residual values, and the distribution of the data about the best-fit line
for each model (e.g., as given by the residual plots for each set of data). The results of
this approach were then used to ascertain the type of binding that was occurring between
the drug and lipoprotein, the number of moles of active binding sites present for the drug
within the column, the association equilibrium constants for the interactions that were
occurring. The results of this experimentation are described in later chapters of this
dissertation.

Overall Goal and Summary of Work
The overall goal of this dissertation is to examine the use of HPAC in the
evaluation of type and strength of interactions that occur between pharmaceutical drugs
and lipoproteins. This work is needed to improve the speed and accuracy involved with
measurement of drug-lipoprotein interactions and gain a more complete understanding of
such interactions within the body. The studies provided in Chapter 2 examine the
interactions that occur between the drugs propranolol and verapamil and HDL. This
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work focused on previously unidentified binding between the drugs and apolipoproteins
on the surface of HDL. Chapter 3 describes the extension of the methods developed in
work with HDL to LDL. The work presented in this chapter also examined the presence
of stereoselective binding of propranolol by apolipoprotein B100. Chapter 4 addresses
the application of the HPAC methods to the study of interactions between propranolol
and VLDL. The binding constants determined in Chapters 2, 3, and 4 were evaluated
against established literature values. Chapter 5 then utilizes theoretical modeling to
examine the experimental conditions necessary to determine the type of multi-site
interactions that were ascertained in earlier chapters. Finally, Chapter 6 discusses
potential future studies that can utilize the methods developed in this dissertation.

47
References
1.

Otagiri, M. Drug Metab. Pharmacokinet. 2005, 20, 309–323.

2.

Bertucci, C.; Domenici, E. Curr. Med. Chem. 2002, 9, 1463.

3.

Hage, D.S. J. Chromatogr. B. 2002, 768, 3-30.

4.

Lindup, W.E. In Progress in Drug Metabolism, Vol. 10; Bridges, J.W.;
Chasseaud, L.F.; Gibson G.G. Eds.; Tylor & Francis: New York, 1987, Ch. 4.

5.

Kwong, T.C. Clin. Chim. Acta 1985, 151, 193–216.

6.

Svensson, C.K.; Woodruff, M.N.; Baxter, J.G.; Lalka, D. Clin. Pharmacokinet.
1986, 11, 450-469.

7.

Wainer, I.W. Trends Anal. Chem. 1993, 12, 153-158.

8.

Hage, D.S.; Tweed, S.A. J. Chromatogr. B. 1997, 699, 499-525.

9.

Hage, D.S.; Chen, J. In Handbook of Affinity Chromatography; Hage, D.S. Ed.;
CRC Press/Taylor & Francis: New York, 2006, pp 595–628.

10.

Hage, D.S.; Jackson, A.; Sobansky, M.; Schiel, J.E.; Yoo, M.Y.; Joseph, K.S. J.
Sep. Sci. 2009, 32, 835–853.

11.

Kratochwil, N.A.; Huber, W.; Muller, F.; Kansy, M.; Gerber, P.R. Biochem.
Pharmacol. 2002, 64, 1355-1374.

12.

Jonas, A. In Biochemistry of Lipids, Lipoproteins, and Membranes; Vance, D.E.;
Vance, J.E. Eds.; Elsevier: Amsterdam, 2002, pp 483–504.

13.

Barklay, M. In Blood Lipids and Lipoproteins: Quantitation, Composition, and
Metabolism; Nelson, G.J. Ed.; Wiley: New York, 1972, pp 587–603.

14.

Wasan, K.M.; Cassidy, S.M. J. Pharm. Sci. 1998, 87, 411–424.

48
15.

Harmony, J.A.K.; Aleson, A.L.; McCarthy, B.M. In Biochemistry and Biology of
Plasma Lipoproteins; Scanu, A.M.; Spector, A.A. Eds.; Marcel Dekker: New
York, 1986, pp 403-430.

16.

Mbewu, A.D.; Durrington, P.N. Atherosclerosis. 1990, 85, 1–14.

17.

Durrington, P.N.; In Lipoproteins and Lipids; Durrington, P.N. Ed.; Wright:
London, 1989, pp 255–277.

18.

Havel, R.J.; Kane, J.P. In The Metabolic and Molecular Basis of Inherited
Disease; Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D.; Childs, B.; Kinzler,
K.W.; Vogelstein, B. Eds.; McGraw-Hill: New York, 1995, pp 1129–1138.

19.

Skipski, V.R.; In Blood Lipids and Lipoproteins Quantitation, Composition, and
Metabolism; Nelson, G.J. Ed.; John Wiley: New York, 1972, pp 471–583.

20.

Glasson, S.; Zini, R.; D’Athis, P.; Tillement, J.P. ; Boissier, J.R. Mol. Pharmacol.
1980, 17, 187–191.

21.

Ohnishi. T.; Mohamed, N.A.L.; Shibukawa, A.; Kuroda, Y.; Nakagawa, T.; El
Gizawy, S.; Askal, H.F.; El Kommos, M.E. J. Pharm. Biomed. Anal. 2002, 27,
607–614.

22.

Mohamed, N.A.L.; Kuroda, Y.; Shibukawa, A.; Nakagawa, T.; El Gizawy, S.;
Askal, H.F.; El Kommos, M.E. J. Chromatogr. A. 2000, 875, 447–453.

23.

Mohamed, N.A.L.; Kuroda, Y.; Shibukawa, A.; Nakagawa, T.; El Gizawy, S.;
Askal, H.F.; El Kommos, M.E.; J. Pharm. Biomed. Anal. 1999, 21, 1037–1043.

24.

Chen, S.; Sobansky, M.; Hage, D.S. Anal. Biochem. 2010, 397, 107-114.

25.

Sobansky, M.R.; Hage, D.S. Anal. Bioanal. Chem. 2012, 403, 563-571.

26.

Walters, R.R. Anal. Chem. 1985, 57, 1099A-1101A.

49
27.

Hage, D.S. In Handbook of Affinity Chromatography; Hage, D.S. Ed.; CRC
Press/Taylor & Francis: New York, 2006.

28.

Ettre, L.S. Pure Appl. Chem. 1993, 65, 819-872.

29.

Sobansky, M.R.; Hage, D.S. Anal. Bioanal. Chem. 2014, 406, 6203-6211.

30.

Borga, O.; Azarnoff, D.L.; Forshell, G.P.; Sjoqvist, F. Biochem. Pharmacol.
1969, 18, 2135-2143.

31.

Piafsky, K.M.; Borga, O. Clin. Pharmacol. Ther. 1977, 22, 545-549.

32.

Hollósy, F.; Valkó, K.; Hersey, A.; Nunhuck, S.; Kéri, G.; Bevan, C. J. Med.
Chem. 2006, 49, 6958-6971.

33.

Kwong, T.C. Clin. Chim. Acta 1985, 151, 193–216.

34.

Nelson, D.L.; Cox, M.M.; In Lehninger Principles of Biochemistry, 4th ed; W.H.
Freeman: New York, 2005.

35.

Sager, G.; Nilsen, O.G.; Jacobsen, S. Biochem. Pharmacol. 1979, 28, 905-911.

36.

Pike, E.; Skuterud, B.; Kierulf, P.; Lunde, P.K.M. Clin. Pharmacol. Ther. 1982,
32, 599-606.

37.

Bicke, M.H. J. Pharm. Pharmacol. 1975, 27, 733-738.

38.

Pike, E.; Kierulf, P.; Skuterud, B.; Bredesen, J.E.; Lunde, P.K.M. Br. J. Clin.
Pharmacol. 1983, 16, 233-239.

39.

Verbeeck, R.K.; Cardinal, J.A.; Allison, G.; Midha, K.K. Biochem. Pharmacol.
1983, 32, 2565-2570.

40.

Hebb, A.R.; Godwin, T.F.; Gunton, R.W. Canad. Med. Assoc. J. 1968, 98, 246251.

50
41.

Hansson, L.; Malmerona, R.; Olander, R.; Rosenhall, L.; Westerlund, A.; Aberg,
H.; Hood, B. Klein. Wschr. 1972, 50, 364-369.

42.

Harrison, D.C.; Griffin, J.R.; Fiene, T.J. N. Engl. J. Med. 1965, 273, 410-415.

43.

Henry, J.A.; Dunlop, A.W.; Mitchell, S.N.; Turner, P.; Adams, P. J. Pharm.
Pharmacol. 1981, 33, 179-182.

44.

Plumb, R.S.; Potts III, W.B.; Rainville, P.D.; Alden, P.G.; Shave, D.H.; Baynham,
G.; Mazzeo, J.R. Rapid Commun. Mass Spectrom. 2008, 22, 2139-2152.

45.

Rossi, S. In Australia Medicines Handbook; Rossi, S. Ed.; Australian Medicines
Handbook Pty. Ltd.: Aldelaide, 2006.

46.

Hasegawa, J.; Fujita, T.; Hayashi, Y.; Iwamoto, K.; Watanabe, J. J. Pharm. Sci.
1984, 73, 442-445.

47.

I. Moriguchi, S. Hirono, I. Nakagome, H. Hirano. Comparison of reliability of
log P values for drugs calculated by several methods. Chem. and Pharm. Bulletin.
42 (1994), 976-978.

48.

Gustavsson, P.E.; Larsson, P.O. In Handbook of Affinity Chromatography, 2nd ed.;
Hage, D.S. Ed.; CRC Press: Boca Raton, 2006.

49.

Mallik, R.; Hage, D.S. J. Sep. Sci. 2006, 29, 1686-1704.

50.

Mallik, R.; Jiang, T.; Hage, D.S. Anal. Chem. 2004, 76, 7013-7022.

51.

Mallik, R.; Hage, D.S. J. Pharm. Biomed. Anal. 2008, 46, 820-830.

52.

Hage, D.S.; Anguizola, J.; Barnaby, O.; Jackson, A.; Yoo, M.J.; Papastavros, E.;
Pfaunmiller, E.; Sobansky, M.; Tong, Z. Curr. Drug Metab. 2011, 12, 313-328.

53.

Kim, H.S.; Hage, D.S. In Handbook of Affinity Chromatography, 2nd ed.; Hage
D.S. Ed.; CRC Press: Boca Raton, 2006.

51
54.

Sobansky, M.R.; Hage, D. S. In Advances in Medicine and Biology, Vol 53;
Berhardt, L.V. Ed.; Nova: New York, 2012.

52
CHAPTER TWO
ANALYSIS OF DRUG INTERACTIONS WITH HIGH DENSITY LIPOPROTEIN
BY HIGH-PERFORMANCE AFFINITY CHROMATOGRAPHY

Portions of this chapter have previously appeared in S. Chen, M.R. Sobansky, and D.S.
Hage, “Analysis of drug interactions with high-density lipoprotein by high-performance
affinity chromatography", Analytical Biochemistry 2010, 397, 107-114.

INTRODUCTION
Lipoproteins, including HDL, are soluble macromolecular complexes of proteins
and lipids that are present in the serum to transport hydrophobic compounds, such as
cholesterols and triglycerides [1-3]. These complexes are also responsible for binding
several basic and neutral hydrophobic drugs, including propranolol and verapamil [4].
The interactions that occur between drugs and biological agents, such as high density
lipoprotein (HDL) and other lipoproteins, is important in determining the activity,
pharmacokinetics and toxicity of drugs in the human body, as many drugs can undergo
reversible interactions with serum proteins and lipoproteins [5-7]. This process impacts
the distribution, delivery, metabolism, and excretion of these drugs [5-10]. As a result,
the pharmaceutical industry often performs protein binding studies when designing a
drug and in determining an appropriate mode of drug delivery capable of effectively
treating a disease [7,8,11].
Propranolol and verapamil (refer to structures in Figure 1-4) are both known to
interact with HDL. Equilibrium dialysis has been used to examine the binding of
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propranolol to HDL, and a method based on frontal analysis and CE has been used to
study the interactions of propranolol and verapamil to HDL and other lipoproteins [1215]. The overall affinity constants that have been measured for propranolol and
verapamil with HDL in these reports are summarized in Table 2-1 [12-15].
In this chapter, HPAC was employed as a tool to study the interactions of
propranolol with HDL. The stability of the HDL columns was evaluated by using zonal
elution studies, as described in Chapter 1. An analysis of the binding mechanisms of the
immobilized HDL for R- and S-propranolol and racemic verapamil was investigated by
using frontal analysis. The ensuing results were compared to data obtained in previous
studies utilizing soluble HDL in equilibrium dialysis or high-performance frontal
analysis/CE. The overall objective of these studies were to test the feasibility of using
immobilized HDL with HPAC in drug binding studies and for providing additional
information on the nature of the interaction between propranolol with HDL in the
circulation.

Table 2-1

Reported binding parameters for the interactions of propranolol and verapamil with HDL

Analyte

Overall affinity, nKa
(M-1)

Method and reference

Racemic
propranolol

1.60 (± 0.14) x 104

Equilibrium Dialysis [12]

R-propranolol

2.38 (± 0.14) x 104

High-performance frontal analysis /
capillary electrophoresis [13]

S-propranolol

2.43 (± 0.15) x 104

High-performance frontal analysis /
capillary electrophoresis [13]

R-verapamil

2.75 (± 0.61) x 104

High-performance frontal analysis /
capillary electrophoresis [14]

S-verapamil

2.81 (± 0.33) x 104

High-performance frontal analysis /
capillary electrophoresis [14]

Experimental conditions
pH 7.4 phosphate buffer (0.66M)
13 µM HDL, 37 ᵒC
pH 7.4 phosphate buffer
(I = 0.17)
14.6 µM HDL, 37 ᵒC
pH 7.4 phosphate buffer
(I = 0.17)
14.6 µM HDL, 37 ᵒC
pH 7.4 phosphate buffer
(I = 0.17)
14.6 µM HDL, 37 ᵒC
pH 7.4 phosphate buffer
(I = 0.17)
14.6 µM HDL, 37 ᵒC
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EXPERIMENTAL
Reagents
The human HDL (catalog number L1567, lot no. B73112), R-propranolol, Spropranolol, and racemic R/S-verapamil were obtained from Sigma (St. Louis, MO,
USA). Macherey Nagel (Düren, Germany) was provided Nucleosil Si-300 silica (7 µm
particle diameter, 300 Å pore size). All reagents for bicinchoninic acid (BCA) protein
assay were purchased from Pierce (Rockford, IL, USA). A total cholesterol assay test kit
was obtained from Wako (Richmond, VA, USA). All other unspecified chemicals were
of the highest grades available. All solutions were prepared using water from a Nanopure
purification system (Barnstead, Dubuque, IA, USA) that was filtered with Osmonics 0.22
µm nylon filters from Fisher Scientific (Pittsburgh, PA, USA).

Apparatus
The high performance liquid chromatograph consisted of two PU-980 pumps
(Jasco, Tokyo, Japan), one LabPro injection valve (Rohnert Park, FL, USA), and a
UV/Vis SpectroMonitor 3200 variable wavelength absorbance detector from LDC
Thermoseparations (Riviera Beach, FL, USA). Chromatographic data were collected and
processed using programs based on Labview 5.1 or 7.0 (National Instruments, Austin,
TX, USA). Stationary phase was packed into stainless steel columns using a slurry
packer from Alltech (Deerfield, IL, USA). A PolyScience circulating water bath from
VWR (Buffalo Grove, IL, USA) was used to control the temperature of columns and
mobile phases.
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Preparation of the HDL support
The immobilization of high density lipoprotein on a silica support followed the
general procedure outlined in Chapter 1. The first step in the process was to prepare a
diol-bonded phase from Nucleosil Si-300 silica, which was accomplished according to a
published procedure [16,17]. This protocol provided a surface utilized in a modified
form of the Schiff base reaction to covalently attach HDL particles to the silica [18]. The
immobilization was successfully completed by placing 0.2 g of the diol-bonded silica into
4 ml of 90:10 (v/v) mixture of acetic acid and water and subsequently adding 0.2 g
periodic acid. The mixture was sonicated under vacuum for 15 min and shaken on a
wrist action shaker for over 2 h in the dark at room temperature. The reaction yielded
aldehyde-activated silica that was rinsed six times with water and four times with pH 6.0,
0.10 M potassium phosphate buffer in preparation for reaction with primary amine
groups.
The immobilization of HDL was begun by suspending the aldehyde-activated
silica in 1 ml of pH 6.0, 0.10 M potassium phosphate buffer and sonicating under vacuum
for 5 min. A 20 mg portion of HDL and 4.3 mg of sodium cyanoborohydride
(NaCNBH4) were added to this slurry and the mixture was shaken in the dark at 4 ºC for
3 days. The resulting immobilized HDL support was rinsed four times with pH 7.0, 0.10
M potassium phosphate buffer. Remaining aldehyde groups on the silica were reduced
by dissolving a 3.4 mg portion of sodium borohydride (NaBH4) in 2 ml of pH 7.0, 0.10 M
potassium phosphate buffer and adding to the HDL support. This mixture was shaken for
90 min at room temperature and subsequently rinsed six times using pH 7.0, 0.10 M
potassium phosphate buffer. The final HDL immobilized support was held in pH 7.0
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buffer at 4 ºC until use. A column with the same dimensions was packed with diol silica
and used as a control. The HDL and control supports were downward slurry packed into
1 cm  2.1 mm i.d. or 5 cm × 2.1 mm i.d. stainless steel columns at 3500 psi using 0.067
M potassium phosphate buffer, pH 7.4, as the packing solution. Portions of each support
were retained for determining immobilization efficiency. The columns were stored in
0.067 M phosphate buffer, pH 7.4, at 4°C when not in use.

Determination of immobilization efficiency
The final HDL support was evaluated to determine the coverage of HDL on the
support. These values were used to determine how much HDL was contained within the
packed HPAC columns and to determine binding constants. Two different procedures
were utilized to determine the HDL immobilization efficiency. The first method was to
determine the protein content of the HDL support using a BCA protein assay [19,20]. To
perform this evaluation, a HDL stock standard was prepared in potassium phosphate
buffer (0.067 M, pH 7.4) and serial dilutions were used to generate a standard curve. A
blank was prepared from diol-bonded silica. The absorbances of the blank and sample
solutions were determined at 562 nm after the solutions were filtered through a 0.2 m
nylon filter. The diol-bonded silica blank response was equivalent to less than 0.1 mg of
protein per gram of silica.
Total cholesterol content of the support was determined by using an enzymatic
colorimetric method [20,21]. As with the BCA assay, a blank was prepared from diolbonded silica. A series of dilutions in potassium phosphate buffer (0.067 M, pH 7.4) was
performed from the standard solution included in the Wako Cholesterol E assay kit to
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generate a standard curve. Samples were prepared by suspending the HDL support and
the diol-bonded silica control support in 0.067 M potassium phosphate buffer, pH 7.4.
An aliquot of working reagent solution (prepared from color reagent and buffer solution
provided with the Wako Cholesterol E assay kit) was added to all samples and standards
as described by the manufacturer. Samples and standards were allowed to react as
described by the manufacturer’s instructions, filtered through a 0.2 m nylon filter, and
absorbance was measured at 600 nm.

Chromatographic studies
Chromatographic studies were conducted using the HPAC apparatus that was
described earlier. Prior to these studies, the HDL column or control column was placed
into HPLC column water jackets from Alltech and connected to a circulating water bath
for equilibration at the desired temperature. All mobile phases were filtered through
Osmonics 0.22 µm nylon filters and degassed under vacuum over 15 min prior to use.
Elution of R- or S-propranolol was monitored at a wavelength of 225 nm, and elution of
R- or S-verapamil was monitored at 229 nm. Sodium nitrate was utilized as a nonretained solute; elution of this compound was monitored at 205 nm.
Zonal elution experiments were performed as described in Chapter 1. These
studies were used in the evaluation of HDL column stability over time. The mobile phase
for the zonal elution studies was a 0.067 M potassium phosphate buffer, pH 7.4. This
buffer was continuously applied to a 1 cm  2.1 mm i.d., column containing the HDL
support at a flow rate of 1.0 ml/min and a temperature of 37 ºC. The void times for the
HDL and control columns were determined by injecting a 20 µL sample of 1 µM sodium
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nitrate. A 20 µL portion of 1 µM samples containing R- or S-propranolol was injected
onto the HDL column (and also initially on the control column) every 12 h for over 300 h
to evaluate changes in the retention properties of the HDL support. The central moment
for each peak was determined using Seasolve Peakfit 4.12 software and reported as the
retention time for each peak.
Frontal analysis studies were conducted to examine the binding of R- and Spropranolol with immobilized HDL as described in Chapter 1. These studies were
conducted using a 5 cm  2.1 mm i.d. column packed with the HDL support or control
support. Measurements were made in the presence of 0.067 M potassium phosphate
buffer pH 7.4, at a flow rate of 1.0 ml/min. The temperature for the studies was set at 4
ºC, 27 ºC or 37 ºC. Slight modifications to the flow rate (between 0.4 and 1.2 ml/min)
resulted in less than a 2% change in the measured binding capacities. All determinations
were achieved within the first 60 h of operation for each new HDL column. This time
frame was within the usable time range determined during zonal elution studies.
Solutions containing between 0.1-25 µM R- or S-propranolol or 0.25-10 µM R- or Sverapamil dissolved in the mobile phase were applied to the HDL column and control
column. A total of eleven different concentrations of each propranolol enantiomer and
six different concentrations of each verapamil were applied and analyzed during the
frontal analysis studies. Elution of retained compounds was accomplished by passing
0.067 M potassium phosphate buffer, pH 7.4, through the column prior to the next frontal
analysis experiment. The frontal analysis experiments generated breakthrough curves [7]
that were integrated using Labview 5.1. Based upon the integration of this breakthrough
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curve, the amount of drug that required to saturate the HDL column or control column
was determined.
Non-specific interactions with system components other than HDL comprised
approximately 5-15% of the total retention noted for R- and S-propranolol and 15-22% of
the total retention of R- and S-verapamil on the HDL column. These values are known to
vary between analytes and must be evaluated on a case-by-case basis [7,22]. The values
reported in this dissertation were determined by analysis of the breakthrough curves
obtained on the HDL and control columns. Corrections were made for non-specific
binding and the void time by subtracting the breakthrough time of the control column
from that of HDL column at each concentration of drug as has been reported in past
studies with the same drugs and other HPLC supports or binding agents [9,10,22,23].

RESULTS AND DISCUSSION
Composition and stability of the HDL support
The composition of the HDL support was examined by using both the BCA
protein assay and the cholesterol assay, as described in the previous sections. The results
of the BCA assay indicated that the support contained 68 (± 5) mg HDL per gram silica.
The cholesterol assay indicated that the total cholesterol content of the support was 3.4 (±
0.4) mg cholesterol per gram silica. The protein and cholesterol content of the HDL
support gradually decreased during long term storage in 0.067 M phosphate buffer, pH
7.4. The magnitude of this change was approximately the same for both the protein and
cholesterol content, with the protein content decreasing by 43 (± 4)% and the cholesterol
content decreasing by 56 (± 7)% over three months. The consistent rate of change in
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both the cholesterol and protein content measured before and after three months of
storage indicated that these changes in the composition of the support were due to loss of
intact HDL particles and not the selective loss of apolipoproteins or cholesterol.
Although the stability of columns containing immobilized lipoproteins during
storage is important for HPAC methodologies, this does not prove their stability when
used in a flow-based system. The fact that lipoproteins are macromolecular congregates
that are held together by non-covalent interactions may make them more susceptible to
degradation or collapse than traditional binding agents such as HSA or AGP [1,2]. The
fact that approximately half of the original HDL particles were still immobilized to the
silica support following three months of storage in buffer initially demonstrated that the
HDL support might be suitable for use over shorter periods of time in a flow-based
system employed in HPAC studies.
The stability of the HDL support in a flow-based chromatographic system was
evaluated using zonal elution experiments in which injections of R- or S-propranolol were
made onto this column over time. The retention of R-propranolol on the immobilized
HDL support over time is shown in Figure 2-1. Similar results were obtained for Spropranolol. In this study, the first injection of R-propranolol occurred after 10 ml of
mobile phase had passed through the new HDL column. Reproducible retention was
obtained over the first five days (120 h) of use. During this time period, the HDL column
retained R-propranolol for approximately 39 to 41 s, corresponding to a retention factor
(k or k’) of 2.6 to 2.7. The amount of mobile phase that was passed through this column
during the first five days of use was 7.2 L, which was equivalent to 3.6  104 column
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volumes. These data confirmed that the HDL column was sufficiently stable for drug
binding studies under such conditions.
Following the first five days of use, a gradual decrease in the retention of R- and
S-propranolol on the HDL column occurred. This can be exemplified by evaluating the
retention of R-propranolol after 12 days of continuous operation; after this time period,
the retention factor for R-propranolol diminished from its original value of 2.6-2.7 to just
over 1.0. This change corresponded to a decrease of roughly 9% per day after the first
five days of use. Enantiomeric selectivity for R- or S-propranolol was not observed with
the HDL column at any time during this study; which supports previously reported results
obtained using CE-frontal analysis [13].
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Figure 2-1.

Change in the retention factor for R-propranolol as function of mobile
phase volume. The mobile phase was 0.067 M phosphate buffer, pH 7.4,
which was passed through a 1 cm  2.1 mm i.d. HDL column at 1 ml/min
and 37oC for up to 300 h. This Figure is reproduced with permission from
Ref. [24].
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Frontal analysis studies of propranolol binding to HDL.
Frontal analysis studies were initiated to determine the binding capacity and
equilibrium binding constants for interactions that may occur between R/S-propranolol
and HDL. The data were collected within the first 120 h of column preparation, as this
was the period of time in which HDL columns were previously determined to be stable.
Typical frontal analysis breakthrough curves are shown in Figure 2-2. These curves were
obtained while analyzing R-propranolol on the HDL columns. The mean position of each
breakthrough curve (mLapp) was determined via integration and used in conjunction with
the known concentration of applied drug ([A]) to generate double-reciprocal plots of
1/mLapp versus 1/[A]. When a single type of binding is present, this type of plot should
result in a linear relationship. In the event of multiple types of binding are present, the
double-reciprocal plot will show negative deviations from linear at high analyte
concentrations or low values of 1/[A] [7]. The double-reciprocal plots for R- and Spropranolol interactions with HDL at each temperature examined in this study resulted in
a negative deviation at low values of 1/[A]. This deviation was indicative of multiple
interactions between R- and S-propranolol and HDL. A representative double-reciprocal
plot is shown in Figure 2-3.
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Figure 2-2.

Typical frontal analysis results obtained for the application of Rpropranolol to a 2.1  50 mm HDL column at analyte concentrations of
0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 5, 10 or 25 µM. These results were obtained at
1.0 ml/min and 37ºC in the presence of 0.067 M phosphate buffer, pH 7.4.
This Figure is reproduced with permission from Ref. [24].
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Figure 2-3.

Double-reciprocal plot of frontal analysis data obtained for the binding of
R-propranolol to a 2.1  50 mm HDL column at 37oC and in the presence
0.067 M phosphate buffer, pH 7.4, at a flow rate of 1.0 ml/min. The best
fit line was obtained using data points in the upper region of this plot,
which are designated by the closed squares (■) and cover R-propranolol
concentrations that ranged from 0.1 M to 2.5 M. Data points in the
lower region of this plot (i.e., at higher concentrations of R-propranolol)
showed negative deviations from the linear fit to the upper data points and
are represented by open squares (□). The equation for the best fit line to
the data represented by the closed squares was y = 5.45 (± 0.07)  102 +
2.7 (± 0.6)  108; the correlation coefficient of this best fit line was
0.99985 (n = 12). This Figure is reproduced with permission from Ref.
[24].
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Examination of the double-reciprocal plots revealed that multiple types of
interactions were present and indicated that further analysis was necessary to determine
the nature of the interactions that were occurring between R/S-propranolol and HDL.
Therefore, the frontal analysis data was next evaluated by using plots of mLapp versus [A]
for R- and S-propranolol. Examination of these plots revealed the presence of a nonlinear relationship; examples are given in Figure 2-4. These data were subsequently fit to
equations representing four distinct binding models (refer to summary in Table 1-2) that
described the potential interactions of the applied drugs with HDL.
One type of binding that may occur between an analyte and HDL is saturable, site
specific binding to apolipoproteins present on the surface of HDL [12-14]. This type of
interaction is represented by the “single group of saturable sites” binding model. The
“two groups of saturable sites” model depicts saturable site-specific binding to multiple
locations and would be expected if the apolipoprotein contained two binding regions.
The second possible type of binding is non-specific binding of the drug with the
phospholipid layer and/or interior hydrophobic core, as represented by the “non-saturable
interaction” binding model [12-14]. The presence of both saturable and non-saturable
binding in combination can also be considered through the fourth binding model. Table
2-2 and Table 2-3 contain the association equilibrium constants, binding capacities, or
global affinity constants that were obtained when fitting the frontal analysis results for
each propranolol enantiomer to the four binding models.

71

Figure 2-4.

Examination of frontal analysis data for R-propranolol on an HDL column
at 37oC when fit according to various binding models. These models were
as follows: (a) one group of non-saturable interactions, (b) one group of
saturable sites, (c) two separate groups of saturable sites, and (d) a group
of non-saturable interactions plus a group of saturable sites. The insets
show the residual plots for the fit of each model to the experimental data.
These results were obtained in the presence of 0.067 M phosphate buffer,
pH 7.4.. The correlation coefficients were as follows: (a) 0.99937, n = 12;
(b) 0.99989, n = 12; (c) 0.99996, n = 12; and (d) 0.99996, n = 12. This
figure is reproduced with permission from Ref. [24].
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Table 2-2

Binding parameters obtained for R-propranolol on a HDL column at various temperaturesa

Binding Model
Temperature
mL1 (mol)
Ka1 (M-1)
mL2 (mol)
Ka2 (M-1)
Non-saturable
4 ᵒC
Interaction
Single group of
4 ᵒC
1.4 (± 0.1) x 10-7
1.2 (± 0.1) x 104
saturable sites
R-Propranolol
Two groups of
4 ᵒC
3.8 (± 3.0) x 10-9
2.0 (± 1.3) x 105
4.5 (± 5.3) x 10-7
2.8 (± 3.7) x 103
saturable sites
Two interactions:
4 ᵒC
6.4 (± 0.8) x 10-9
1.4 (± 0.2) x 105
saturable + non-saturable
Non-saturable
27 ᵒC
Interaction
Single group of
27 ᵒC
1.7 (± 0.1) x 10-7
9.7 (± 0.9) x 103
saturable sites
R-Propranolol
Two groups of
27 ᵒC
4.1 (± 0.2) x 10-7
2.6 (± 0.1) x 103
1.6 (± 0.6) x 10-8
3.8 (± 0.6) x 104
saturable sites
Two interactions:
27 ᵒC
5.4 (± 0.6) x 10-9
1.4 (± 0.2) x 105
saturable + non-saturable
Non-saturable
37 ᵒC
Interaction
Single group of
37 ᵒC
3.0 (± 0.4) x 10-7
4.7 (± 0.7) x 103
saturable sites
R-Propranolol
Two groups of
2.4 (± 13000)
1.5 (± 13000)
6.1 (±13000)
37 ᵒC
2.1 (± 6.7) x 10-7
saturable sites
x 103
x 10-7
x 103
Two interactions:
37 ᵒC
2.2 (± 0.7) x 10-9
1.9 (± 0.8) x 105
saturable + non-saturable
a
The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.
Enantiomer

nKab (M-1)
4.4 (± 0.1) x 104
3.7 (± 0.3) x 104
4.8 (± 0.1) x 104
3.9 (± 0.3) x 104
4.4 (± 0.1) x 104
4.1 (± 0.3) x 104

b

The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of HDL in the column. This latter value was

obtained by using the protein content of the HDL support, which was determined using an average molar mass for HDL of 1.8  105 g/mol.
The best fit model is represented in bold.
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Table 2-3

Binding parameters obtained for S-propranolol on a HDL column at various temperaturesa

Binding Model
Temperature
mL1 (mol)
Ka1 (M-1)
mL1 (mol)
Ka1 (M-1)
Non-saturable
4 ᵒC
Interaction
Single group of
4 ᵒC
1.4 (± 0.1) x 10-7
1.3 (± 0.1) x 104
saturable sites
S-Propranolol
Two groups of
4 ᵒC
2.9 (± 1.7) x 10-7
5.2 (± 3.8) x 103
2.2 (± 1.9) x 10-9
4.4 (± 4.1) x 105
saturable sites
Two interactions:
saturable + non4 ᵒC
7.8 (± 2.5) x 10-9
1.3 (± 0.5) x 105
saturable
Non-saturable
27 ᵒC
Interaction
Single group of
27 ᵒC
2.1 (± 0.2) x 10-7
7.5 (± 0.7) x 103
saturable sites
S-Propranolol
Two groups of
27 ᵒC
5.3 (± 1.3) x 10-7
2.5 (± 0.7) x 103
1.8 (± 0.4) x 10-9
3.0 (± 0.7) x 105
saturable sites
Two interactions:
saturable + non27 ᵒC
3.9 (± 0.2) x 10-9
1.6 (± 0.1) x 105
saturable
Non-saturable
37 ᵒC
Interaction
Single group of
37 ᵒC
2.2 (± 0.1) x 10-7
6.8 (± 0.5) x 103
saturable sites
S-Propranolol
Two groups of
37 ᵒC
5.3 (± 1.6) x 10-7
2.4 (± 0.8) x 103
1.9 (± 0.7) x 10-9
2.0 (± 0.6) x 105
saturable sites
Two interactions:
saturable + non37 ᵒC
4.5 (± 0.2) x 10-9
1.1 (± 0.1) x 105
saturable
a
The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.
Enantiomer

nKab (M-1)
4.8 (± 0.1) x 104
3.9 (± 0.3) x 104
4.4 (± 0.1) x 104
4.0 (± 0.3) x 104
4.4 (± 0.2) x 104
3.7 (± 0.2) x 104

b

The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of HDL in the column. This latter value was

obtained by using the protein content of the HDL support, which was determined using an average molar mass for HDL of 1.8  105 g/mol.
The best fit model is represented in bold.
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Double-reciprocal plots for the frontal analysis data indicated that multiple types
of interactions between R- and S-propranolol and immobilized HDL were present, which
was confirmed by the non-reciprocal plots shown in Figure 2-4, These plots provided a
better fit with models involving more than one type of interaction.

The models

describing situations that contained single interactions did give acceptable correlation
coefficients; however, the residual plots for these both these fits (see Figure 2-4 insets)
resulted in a non-random pattern of data points about the best-fit line. Meanwhile, the
two site binding models resulting in higher correlation coefficients (0.9998 or higher),
lower residuals and a random distribution of the data about the best-fit line.
Further analysis of the two models involving multiple interactions generated
additional information about the binding occurring in the drug-HDL systems. As
depicted in Figure 2-4, the model based on two groups of saturable/non-saturable
interactions (Figure 2-4c) resulted in essentially the same correlation coefficient (e.g.,
values for r greater than 0.9999) and residual plot as the two-site saturable model (Figure
2-4d). Despite the similarity between the two plots, the saturable/non-saturable model
generated precise best-fit equilibrium constants (i.e., refer to the standard deviations
listed for the Ka1, mL1 and n Ka values for this model versus those listed for Ka1, mL1, Ka2
and mL1 in the model based on two groups of saturable sites). The differences in
precision of the equilibrium constants can be explained by the fact that as Ka2 [D] in the
denominator of the model representing two groups of saturable sites approaches zero, the
equation for this model approaches that of a model based on the presence of one saturable
and one non-saturable interaction (refer to expressions in Table 1-2). This situation
occurred in the fit of the two groups of saturable sites model to the frontal analysis data

76
obtained for R- and S-propranolol interactions with HDL. The fact that under these
conditions both fits are describing the same overall model in which a high affinity
saturable site and a lower affinity, essentially non-saturable site is present explains the
large uncertainly that resulted for the two groups of saturable sites fit and explains why
the residual plots in Figures 2-4c and Figure 2-4d are so similar. The binding model
where there was one high affinity saturable binding site and one lower affinity nonsaturable interaction gave the best fit to the frontal analysis data.
The binding model based on two types of interactions, one saturable and one nonsaturable, yielded the best fit equilibrium binding constants for R- and S-propranolol with
HDL that are shown in bold in Tables 2-2 and 2-3 . The association equilibrium constant
(Ka1) for the saturable interaction of HDL with R-propranolol had a value of 1.9 (± 0.8) ×
105 at 37ºC, and S-propranolol had a Ka1 of 1.1 (± 0.1) × 105 at 37ºC. These values
represent relatively high affinity and specific binding that is likely occurring between
propranolol and apolipoproteins on the surface of HDL [6-10]. This is supported by a
closer examination of the mL1 values that were obtained with the moles of
apolipoproteins that were estimated to be present in the HDL column (see following
discussion). The second interaction that was identified represented low affinity and nonspecific binding. This interaction had an overall affinity of 4.1 (± 0.3)  104 M-1 at 37ºC
for R-propranolol with HDL and 3.7 (± 0.2)  104 M-1 at 37ºC for S-propranolol. This
non-specific interaction is believed to occur between R- or S-propranolol and
phospholipids or the non-polar core of HDL, as has been suggested in previous studies
[12,13].
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The impact temperature has on the interactions between R- and S-propranolol and
HDL was also evaluated. The equilibrium binding constants determined for R- and Spropranolol with HDL are provided in Tables 2-2 and 2-3. Examination of the binding
constants revealed that no appreciable effect on the magnitude of each association
equilibrium constant with a change in temperature between 4oC and 37oC. The Ka1
values obtained for both R- and S-propranolol were all in the range of 1.3 to 1.9  105 M1

, and the nKa2 values fell in the range of 3.7 to 4.1  104 M-1. In each case, the

correlation coefficients for frontal analysis plots, analyzed according to a saturable/nonsaturable model, were greater than 0.9999. The Ka1 and nKa2 values that were obtained
utilizing this model for the R- and S-enantiomers of propranolol overlapped within a
range of ± 1 S.D. and were statistically equivalent at each temperature. This statistical
equivalence between both types of interactions in this two site model indicated that
interactions between R/S-propranolol and HDL were not stereoselective. This is the same
conclusion suggested by the binding data reported in Ref. [13] (see Table 2-1).
Furthermore, the binding constants measured for the low affinity interactions in this study
was in agreement with the values reported in Ref. [13] at 37 °C when using a model
based on a single type of non-saturable interaction.
Further examination of the high affinity binding sites was performed by
comparing the measured binding capacity of this site with the known composition of the
HDL support. The total moles (mL1) of these high affinity binding sites, as determined
through frontal analysis, were in the range of 2.2 to 7.8 nmol for both R- and Spropranolol between 4 and 37°C (averages, 4.7 nmol and 5.4 nmol, respectively). As was
previously shown, the BCA assay conducted during the evaluation of the support
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indicated that 30 (± 2) nmol of HDL particles were present in the column. The relatively
strong binding constants determined for the high affinity sites and the fact that their
binding capacity was less than the total moles of HDL in the column strongly supported
the conclusion that the apolipoproteins were culpable for these interactions. The fact that
the binding capacities determined for the high affinity regions were less than the total
number of HDL particles is likely related, in part, to immobilization effects. Previous
studies have shown that immobilization effects are typically responsible for roughly a
50% loss in protein activity when using the Schiff base coupling method employed in this
report (refer to Ref. [7] and references cited therein). In addition, an HDL particle
contains multiple types of apolipoproteins per particle (i.e., up to 5-6 maximum) [1]. In
a situation where only certain types of apolipoproteins are involved in this interaction, it
is expected that the binding capacity is less than the total moles of HDL particles.
Typical HDL apolipoprotein levels are ApoA1 (70%), ApoA2 (20%), and minor
apolipoproteins (Apo E and Apo Cs, with 10% total) [1]. Further research is required to
determine if there are indeed only particular apolipoproteins in this group that bind to Rand S-propranolol.
The typical concentrations R- and S-propranolol in clinical samples was used to
evaluate the relative impact of the selective versus non-selective interactions of agents
with HDL. The typical physiological concentration of HDL in serum is 13-14.6 M
[12,13], and the therapeutic range of propranolol in serum is 0.19-0.39 µM [25].
According to the data presented in Tables 2-2 and 2-3 for the saturable and non-saturable
binding model, the high affinity sites on HDL are responsible for 25-40% of the binding
that is occurring between R- and S-propranolol and this lipoprotein under such
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conditions. These high affinity sites are estimated to have been 85-97% saturated by Ror S-propranolol during the CE binding studies in Ref. [13]. Furthermore, the high
affinity binding sites would have accounted for only 1-10% of the overall drug binding
measured at the concentrations that were used in Ref. [13]. This explains why these
interactions were not directly observed in this later study. A wider range of R- and Spropranolol concentrations was used with the measurements made using equilibrium
dialysis [12]. However, the typical concentrations used in these studies were also
sufficiently large to have made detection of the high affinity interactions possible. In
addition, it is important to remember that even in this study a relatively good fit occurred
for the data with a single site, non-saturable model (see Figure 2-4) and the detection of
two types of interactions between R- and S-propranolol and HDL was only possible
through a close evaluation of this data and comparison of the frontal analysis data with
several interaction models.

Frontal analysis studies of verapamil binding to HDL
As discussed in Chapter 1, the second drug that was used to evaluate binding by
the HDL columns was verapamil. Studies were performed using racemic verapamil
because HDL has been previously reported to have no stereoselective interactions with Rand S-verapamil [14]. Furthermore, evaluation of R- and S-propranolol binding in this
study also indicated free of stereoselective binding to HDL.
Figure 2-5 shows a double-reciprocal plot of frontal analysis data that was
obtained for verapamil on an HDL column. As was reported with propranolol, these
results yield deviations from a linear response at high concentrations of verapamil.
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Furthermore, analysis of non-reciprocal plots using the same data showed that the
response deviated from the linear behavior predicted for only a non-saturable binding
model (see equation in Table 1-2), with a correlation coefficient of r = 0.9952 (n = 6)
obtained for the fit. While this correlation coefficient was reasonable, the model also
gave a non-random distribution of data about the best fit line. A higher correlation
coefficient (r = 0.9999) was obtained when using a model based on a single group of
saturable sites, but this model was eliminated based upon the non-linearity observed in
the double-reciprocal plot.
As with R- and S-propranolol, the binding model that yielded the best fit for the
frontal analysis data for verapamil was based on a group of saturable sites and a set of
non-saturable interactions (refer to summary in Table 2-4). The correlation coefficient
for this binding model was r = 0.9999, and a random distribution of data about the best fit
line was seen in the residual plot. In this fit, the sites responsible for saturable binding
had an association equilibrium constant for verapamil of 6.0 (± 2.1) × 104 M-1 at 37 ᵒC.
The non-saturable interaction of verapamil with HDL had an estimated overall affinity of
2.5 (± 1.5) × 104 M-1. These values supported the overall affinities of 2.7-2.8 × 104 M-1
that were previously reported for the binding of R- and S-verapamil with soluble HDL
[14]. Plots of each fit are shown in Figure 2-6.
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Figure 2-5.

Double-reciprocal plot of frontal analysis data obtained for the binding of
racemic verapamil to a 2.1  50 mm HDL column at 37oC in the presence
of 0.067 M phosphate buffer, pH 7.4, at a flow rate of 1.0 ml/min. The
best fit line was obtained using data points in the upper region of this plot,
which are designated by the closed squares (■) and include verapamil
concentrations that range from 0.25 M to 0.5 M. Data points in the
lower region of this plot (i.e., at concentrations of verapamil from 1 M to
10 M) that showed negative deviations from the linear fit to the upper
data points are represented by open squares (□). The equation for the best
fit line to data represented by the closed squares is y = 2.38 (± 0.01)  102
+ 5.78 (± 0.3)  107; the correlation coefficient of this best fit line was
0.9999 (n = 6).
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Figure 2-6.

Examination of frontal analysis data for verapamil on an HDL column at
37oC according to various binding models. These models were as follows:
(a) one group of non-saturable interactions, (b) one group of saturable
sites, (c) two separate groups of saturable sites, and (d) a group of nonsaturable interactions plus a group of saturable sites. The insets show the
residual plots for the fit of each model to the experimental data. These
results were obtained in the presence of pH 7.4, 0.067 M phosphate buffer.
The correlation coefficients were as follows: (a) 0.9952, n = 6; (b) 0.9999,
n = 6; (c) 0.9999, n = 6; and (d) 0.9999, n = 6.
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Table 2-4
Compound

Verapamil

Binding parameters obtained for racemic verapamil on a HDL column at 37ᵒCa
Binding Model
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + nonsaturable

Temperature

mL1 (mol)

Ka1 (M-1)

mL2 (mol)

Ka2 (M-1)

nKab (M-1)

37 ᵒC

-

-

-

-

9.9 (± 0.3) x 104

37 ᵒC

9.4 (± 0.2) x 10-8

4.2 (± 0.1) x 104

-

-

-

37 ᵒC

4.3 (± 410) x 10-8

6.3 (± 200) x 104

8.6 (± 260) x 10-8

1.5 (± 240) x 104

-

37 ᵒC

5.4 (± 1.6) x 10-8

6.0 (± 2.1) x 104

-

-

2.5 (± 1.5) x 104

a

The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.

b

The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of HDL in the column. This latter value was
obtained by using the protein content of the VLDL support, which was determined by using an average molar mass for HDL of 1.8  105 g/mol.
The best fit model is represented in bold.
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A model based on two groups of saturable sites resulted in a good fit to the data
(refer to Figure 2-6), as evidenced by a correlation coefficient of r = 0.9999. The
equilibrium binding constants predicted by this model both had moderate or lower
affinities for verapamil. This model gave an association equilibrium constant of 6.3 (±
2.0) × 104 M-1 for the first group of saturable binding sites for verapamil on HDL. This
value is similar to that generated for the saturable binding site in the saturable/nonsaturable model.

The second group of saturable sites had an estimated association

equilibrium constant of 1.5 × 104 M-1; however, this value had a large uncertainty of ±
2.4 × 106 M-1. Similar to the propranolol studies, this uncertainty was due to the fact that
the two-site saturable model is approaching the saturable/non-saturable model and
describing same type of behavior. Therefore, it was determined that the saturable/nonsaturable model provided a more appropriate description of the verapamil-HDL
interaction. This conclusion is consistent with the outcome of the experiments conducted
with R- and S-propranolol on the HDL columns.
The overall affinities obtained for the non-saturable interactions of verapamil and
propranolol with HDL were similar. This binding is most likely the result of interactions
between the drugs and phospholipids or the non-polar core of HDL, which has been
previously suggested for both propranolol and verapamil in work with soluble HDL [1214]. The estimated binding affinity of verapamil at its saturable sites on HDL was
significantly smaller than that obtained for propranolol at its saturable regions (i.e.,
roughly one third). However, the two drugs had a much larger difference in the number
of saturable sites that were available for binding. The number of saturable sites available
for verapamil binding was 54 (± 16 nmol) in an HDL column, which was approximately
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10 times greater than the 4.7-5.4 nmol estimated for the saturable sites of R- or Spropranolol. The binding capacity for the saturable binding of verapamil was comparable
to the total moles of immobilized HDL in the column (30 nmol) and the expected moles
of apolipoproteins that were present [1]. These results demonstrated that apolipoproteins
were probably responsible for the saturable binding of verapamil with HDL, as was
suggested earlier for propranolol. The large difference in binding capacities for
verapamil and propranolol at their saturable sites suggest that different apolipoproteins or
different regions on the same apolipoproteins may be interacting with these two drugs.
The R- and S-enantiomers of verapamil have a typical therapeutic concentration
of 0.1 – 0.2 µM in serum [26]. The relative importance of saturable versus non-saturable
interactions in the binding of verapamil with HDL was evaluated using this information
along with the binding parameters in Table 2-4 and the known serum concentration for
HDL (13.0 – 14.6 µM). Under these conditions, the saturable interactions would account
for approximately 70-80% of the overall binding between R- or S-verapamil and HDL
under normal therapeutic conditions. The saturable sites would have accounted for
roughly 40 – 60% of the overall measured binding under the experimental conditions
used in Ref. [14]; however, the similarity in the affinities for the saturable and nonsaturable sites of verapamil and the fact that only a non-saturable model was considered
in Ref. [14] explains why these saturable interactions were not noted in this previous
solution phase study.
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CONCLUSIONS
HDL was used for drug binding studies in HPAC following the immobilization of
HDL in chromatographic columns. Zonal elution experiments demonstrated that the
immobilized HDL column could be used over the course of approximately 5 days of
consistent use without any significant loss of retention for drugs such as R- and Spropranolol. Frontal analysis studies with this type of column revealed that propranolol
and verapamil had two distinct types of interactions with the immobilized HDL. The first
binding mechanism had a high affinity and is likely due to the apolipoproteins on HDL.
The other interaction between the drugs and HDL had a lower affinity and was believed
to be due to non-saturable interactions with the phospholipids or non-polar core of HDL.
The high affinity sites had association constants of 1.1-1.9 × 105 M-1 for R- or Spropranolol and 6.0 × 104 M-1 for R/S-verapamil at 37ºC. The overall affinity (nKa) for
the weaker interactions at 37oC was estimated to be 3.7-4.1  104 M-1 for R- or Spropranolol and 2.5  104 M-1 for R/S-verapamil at 37oC. The non-saturable interaction
values obtained for each drug were in good agreement with the results of previous
solution phase studies [12-14]. There was no evidence of stereoselective interactions
between HDL and the drugs that were analyzed at temperatures ranging from 4 to 37oC.
The results obtained in this work demonstrate the suitability of using immobilized
HDL in high-performance affinity chromatography to study the interactions that occur
between this lipoprotein and drugs or other analytes. When compared with equilibrium
dialysis (i.e., the method used in Ref. [12] and a common reference method for drug
binding studies), primary advantages of this technique are its ability to obtain analysis
times of only a few minutes per run and to reuse the same lipoprotein ligand for many
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experiments. The use of CE with lipoproteins in drug binding studies requires less
protein than the technique described in this study for a single analysis. However, the
ability to reuse HPAC columns that contain immobilized lipoproteins results in a method
that needs a similar amount of ligand when dealing with a large number of samples or
studies. For example, the CE studies in Ref. [13] were conducted using 1.5 pmol HDL
per injection. In this current study, the same HDL column (containing approximately 30
nmol of HDL) was used for over 300 studies, or an average of 10 pmol HDL per analysis.
Furthermore, the ability to use the same HDL preparation for multiple studies decreased
the effects of batch-to-batch variations in the ligand. The ability to utilize HPLC
detectors with such columns allowed for examining a relatively wide range of low and
high drug concentrations and enabled the identification of a high affinity interaction
between HDL and propranolol and verapamil. These interactions were not observed in
previous studies using CE or equilibrium dialysis [12-14]. The sum of these features
demonstrates that columns containing immobilized HDL are powerful tools when used in
the study of drug-lipoprotein interactions by HPAC.
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CHAPTER THREE
IDENTIFICATION AND ANALYSIS OF STEREOSELECTIVE DRUG
INTERACTIONS WITH LOW DENSITY LIPOPROTEIN BY HIGHPERFORMANCE AFFINITY CHROMATOGRAPHY

Portions of this chapter have previously appeared in M.R. Sobansky, and D.S. Hage,
“Identification and analysis of stereoselective drug interactions with low density
lipoprotein by high-performance affinity chromatography", Analytical and Bioanalytical
Chemistry, 2012, 403, 563-571.

INTRODUCTION
The information presented in Chapter 1 demonstrated how the interaction of
drugs with serum proteins and other binding agents in blood is important in determining
the apparent activity, distribution and pharmacokinetics of many pharmaceutical
compounds in the body [1-7]. Lipoproteins, such as low density lipoprotein (LDL), are
one group of serum binding agents that are known to be involved in the interactions with
various drugs and other compounds present in the serum [7-15]. Propranolol (refer to
Figure 1-4) is one drug that has binds with LDL and other lipoproteins. This binding has
been examined with methods based on equilibrium dialysis and CE carried out in a
frontal analysis mode [16-19]. An alternative approach is HPAC, which will be
examined in this report. The HPAC was shown to be suitable for the analysis of druglipoprotein studies with HDL in Chapter 2.

93
In this study, the interactions between propranolol and LDL were evaluated by
using HPAC. This work will build upon the methods that were previously developed for
the examination drug interactions with immobilized HDL [20], as presented in the
previous chapter, and HSA or AGP [3-6,21-26]. The first step in these studies was to
develop a support that contains LDL immobilized on HPLC grade silica. This material
was packed into columns and used in zonal elution and frontal analysis studies, as
described in Chapter 1. The stability of the LDL columns was assessed with zonal
elution studies. Frontal analysis experiments were executed to examine the binding
mechanisms for LDL with R- and S-propranolol at various temperatures, and the results
were compared to measurements obtained with soluble LDL in previous work (refer to
Table 3-1). Additional information regarding the nature of the interactions between Rand S-propranolol with LDL within the body circulation was obtained from these studies.
The advantages and limitations of using immobilized LDL columns with HPAC for drug
binding studies, including those that involve chiral pharmaceutical agents, are also
reported.

Table 3-1

Reported binding parameters for the interactions of propranolol with LDL

Analyte
Racemic
propranolol

Overall affinity, nKa (M-1)

Method and reference

1.76 (± 0.01) x 105

Equilibrium Dialysis [16]

R-propranolol

4.01 (± 0.24) x 105

High-performance frontal analysis
/ capillary electrophoresis [17]

S-propranolol

4.02 (± 0.34) x 105

High-performance frontal analysis
/ capillary electrophoresis [17]

Experimental conditions
pH 7.4 phosphate buffer (0.66M)
1 µM LDL, 37 ᵒC
pH 7.4 phosphate buffer
(I = 0.17)
1.9 µM LDL, 37 ᵒC
pH 7.4 phosphate buffer
(I = 0.17)
1.4 µM LDL, 37 ᵒC
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EXPERIMENTAL
Reagents
Human LDL (catalog number L7914, lot no. 036K1143), bovine serum albumin
(BSA), and the individual enantiomers of R- and S-propranolol were purchased from
Sigma (St. Louis, MO, USA). Nucleosil Si-500 silica (7 µm particle diameter, 500 Å
pore size) was acquired from Macherey Nagel (Düren, Germany). Materials for the
bicinchoninic acid (BCA) protein assay were from Pierce (Rockford, IL, USA). The kit
for performing the total cholesterol assay was purchased from Wako (Richmond, VA,
USA). All other chemicals and reagents were of the highest grades available. Solutions
were prepared using water from a nanopure purification system (Barnstead, Dubuque, IA,
USA) and filtered using Osmonics 0.22 µm nylon filters from Fisher Scientific
(Pittsburgh, PA, USA).

Apparatus
Zonal elution studies utilized a chromatographic system consisting of a PU-980
pump (Jasco, Tokyo, Japan), one LabPro injection valve (Rohnert Park, FL, USA), and a
LDC Thermoseparations (Riviera Beach, FL, USA) UV/Vis SpectroMonitor 3200
variable wavelength absorbance detector. The high performance liquid chromatograph
used in the frontal analysis studies consisted of two 510 HPLC pumps (Waters, Milford,
MA, USA), an F60-AL injection valve (Vici, Houston, TX, USA), a CH-500 column
heater (Eppendorf, Hauppauge, NY, USA) and a Waters 2487 UV/Vis variable
wavelength absorbance detector. Waters Empower software was used to collect the
chromatograms. Chromatographic data were processed using programs based on
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Labview 5.1 or 7.0 (National Instruments, Austin, TX, USA). Supports were placed into
HPLC columns by using a slurry packer from Alltech (Deerfield, IL, USA).

Preparation of LDL support
The LDL support was prepared in an approach similar to the one developed in
Ref. [20] for the immobilization of HDL. This approach utilized a modified version of
the Schiff base reaction to covalently attach LDL to silica. The first step in this process
was to prepare a surface containing a diol-bonded phase from Nucleosil Si-500 silica, as
described previously [26]. Next, a 0.3 g portion of the diol-bonded silica was added to 6
mL of a 90:10 (v/v) mixture of acetic acid and water followed by the addition of 0.3 g
periodic acid. The resulting mixture was sonicated under vacuum for 20 min and mixed
for over 2 h at room temperature while protecting from light to generate aldehydeactivated silica. The silica was subsequently washed four times with water and four
times with pH 6.0, 0.10 M potassium phosphate buffer prior to being placed in 1 mL of
pH 6.0, 0.10 M potassium phosphate buffer and sonicated for 5 min under vacuum. The
addition of 5 mg LDL was preceded by the addition of 20 mg aliquot of sodium
cyanoborohydride. This mixture was mixed at 4 ºC for 7 days while protected from light
exposure. The resulting support containing immobilized LDL was washed four times
with 0.10 M potassium phosphate buffer, pH 7.0. Any remaining aldehyde groups on the
silica were reduced by the slow addition of a 5.2 mg portion of sodium borohydride
dissolved in 2 mL of 0.10 M potassium phosphate buffer, pH 7.0. The resulting slurry
was shaken at room temperature for 90 minutes. The finished LDL stationary phase was
washed six times with pH 7.0, 0.10 M potassium phosphate buffer and stored in the same
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pH 7.0 buffer at 4 ºC until use. Diol-bonded silica was utilized as a control support. The
LDL and control supports were downward slurry packed into 100 mm × 2.1 mm i.d.
stainless steel columns at 3000 psi using pH 7.4, 0.067 M potassium phosphate buffer as
the packing solution.

Determination of immobilization efficiency
A BCA protein assay was used to evaluate the protein content of the LDL support
[28]. The assay was executed in triplicate using BSA solutions prepared 0.067 M
potassium phosphate buffer, pH 7.4, as the standards and diol silica samples as the
blanks. Each sample and standard solution was filtered through a 0.2 m nylon filter
prior to measuring absorbance. Cholesterol content of the immobilized LDL support was
determined using a Wako Cholesterol E assay kit [29]. The sample and standard
solutions were reacted in accordance with the manufacturer’s instructions and filtered
through a 0.2 m nylon filter prior to absorbance measurements. As before, diol-bonded
silica served as the blank. All measurements were made in triplicate. The
immobilization scheme utilized in this report is known to yield good batch-to-batch
reproducibility; a typical batch-to-batch variability in protein content is 5-10% for silica
supports similar to those utilized in this study [4,25,26].

Chromatographic studies
Chromatographic studies were conducted using the HPAC systems described
previously. Different column preparations were utilized for the zonal elution and frontal
analysis studies; however, the columns were prepared from the same batch of the LDL
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support. The LDL and control columns were stored in 0.067 M phosphate buffer, pH 7.4,
at 4°C when not in use. Prior to chromatographic experiments, the columns were
equilibrated at the specified temperature. Mobile phase solutions were filtered through
Osmonics 0.22 µm nylon filters and degassed under vacuum prior to use. A wavelength
of 225 nm was utilized to monitor the elution of R- or S-propranolol. Sodium nitrate was
used as a non-retained solute and was monitored at 205 nm.
The zonal elution experiments were carried out as described in Chapter 1. The
stability of the LDL columns was determined using these experiments. Zonal elution
studies were executed using a pH 7.4, 0.067 M potassium phosphate buffer as mobile
phase. This buffer was applied to a 100 mm  2.1 mm i.d. column containing the LDL
support for 60 h at 37 ºC. The void time of the column was determined by injecting a 20
µL sample of 50 µM sodium nitrate onto the LDL column and control column. The
retention of an injected analyte was monitored by performing 20 µL injections of 50 µM
R-propranolol onto LDL and control columns at 1.0 mL/min. The retention time for each
peak was determined by utilizing Peakfit 4.12 software (Systat Software, San Jose, CA)
to find the central moment of the peak.
Frontal analysis experiments were performed in triplicate using 100 mm  2.1
mm i.d. columns packed with the LDL support or control support. These studies were
conducted using a mobile phase of 0.067 M potassium phosphate buffer, pH 7.4, applied
at 1.0 mL/min. Measurements were made at 20 ºC, 27 ºC, and 37 ºC. Additional details
regarding execution of frontal analysis tests are described in Chapter 1. A total of nine
solutions containing R- or S-propranolol with concentrations ranging from 0.2-25 µM of
0.067 M potassium phosphate buffer, pH 7.4, were applied to the LDL and control

99
columns. The least concentrated solution in this range was selected as it was near the
lowest concentration at which the breakthrough times for R- and S-propranolol could be
reliably determined on this chromatographic system. The upper end of this concentration
range was selected because it provided a signal within the range of linear response for the
detector and overlapped with drug concentrations that have been used in CE/frontal
analysis studies [17]. The retained drug was eluted following frontal analysis
measurements by passing only 0.067 M potassium phosphate buffer, pH 7.4, through the
column prior to the next experiment.
Following the execution of frontal analysis studies, the moles of applied drug
required to saturate the LDL column or control column was determined by integration of
the resulting breakthrough curve [3] by using a program based on Labview 5.1 software.
The impact of the void volume and non-specific binding on the apparent moles of
propranolol required to saturate the support was determined by examining the
breakthrough curve of R- or S-propranolol solutions on the control column. Corrections
were made for these factors by subtracting the breakthrough time of the control column
from that of LDL column at each concentration of drug, as described in Chapter 2. The
non-specific interactions between R- or S-propranolol to the support accounted for
approximately 12% of the total binding noted on the LDL column at an applied analyte
concentration of 25 M. The typical precision of the frontal analysis measurements was
 4-5%. The precision varied between  0.1% and  14% at all of the conditions that
were examined; the precision at even the lowest tested concentrations was  1-7%.
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RESULTS AND DISCUSSION
Composition and stability of the LDL support
The composition of the LDL support was examined by using two methods. The
BCA protein and cholesterol assays were performed in a fashion similar to that described
in Chapter 2. According to the results of the BCA protein assay, the support was
contained 6.9 (± 0.4) mg protein per gram silica. Using an average molar mass of 2.3 
106 g/mol for LDL and a typical apolipoprotein content of 25% for LDL particles, this
protein content converted to 27.7 (± 1.6) mg or 12 (± 1) nmol of LDL per gram silica
[17]. The cholesterol assay results indicated the support contained 7.2 (± 1.1) mg
cholesterol per gram silica; based on a typical cholesterol content of 45% for LDL
particles, which corresponded to 16 (± 2.4) mg of LDL per gram silica [7,8,10,14,17].
The differences in the estimated lipoprotein levels using the two assay methods are
similar to those observed during the HDL studies described in Chapter 2. The nKa
calculated and reported later in this report were determined using the amount of
immobilized LDL based on the protein assay. Calculation of nKa values based on the
cholesterol assay would result in values that are approximately 40% lower.
The chromatographic stability of the LDL support was evaluated using zonal
elution experiments. These experiments were executed by making periodic injections of
R-propranolol onto an LDL column under controlled temperature and flow rate
conditions. The retention for 20 µL injections of 50 µM R-propranolol as a function of
time is shown in Figure 3-1. These chromatograms were obtained when the LDL column
was used at 1 mL/min and 37 ºC for over 60 h. The first injection on the freshly prepared
LDL column occurred after 10 mL of mobile phase (i.e., a time of 10 min at 1.0 mL/min)
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had been applied to the column. The retention of R-propranolol was reproducible over
the next 60 h of continuous use, exhibiting only ± 2% variability. The average retention
time under these conditions was 90.5 (± 1.8) s. This corresponded to a retention factor of
2.90 (± 0.06) and is comparable to the retention noted for the HDL columns in Chapter
2. Over the course of zonal elution experiments, 3.6 L (1.6  104 column volumes) of
mobile phase was passed through the LDL column. This result indicated that, as with the
immobilized HDL columns examined in Chapter 2, the LDL columns were suitable for
drug binding studies carried out under such conditions.

Frontal analysis studies of propranolol binding to LDL
Frontal analysis studies were conducted to evaluate the interactions that occur
between R- or S-propranolol and the LDL support. These experiments were conducted
on a new LDL column within the period of time during which zonal elution studies
indicated the LDL support was stable (i.e., when less than 3600 mL of mobile phase had
passed through the column). Typical breakthrough curves obtained during frontal
analysis experiments with the LDL support are shown in Figure 3-2. The moles of
applied analyte (mLapp) that were required to reach the mean position of each
breakthrough curve were determined via integration of the frontal analysis
chromatograms. This information was used with the known concentration of the applied
drug ([D]) to generate binding isotherms and to fit the data to the binding models
described in Table 1-2 to determine the binding mechanisms that were occurring between
LDL and R- or S-propranolol.
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Figure 3-1.

Chromatograms depicting the change in retention for R-propranolol on an
LDL column as a function of mobile phase volume. The mobile phase
(pH 7.4, 0.067 M phosphate buffer) was passed through a 100 mm × 2.1
mm i.d. LDL column at 37 ᵒC and 1 mL/min. The dashed vertical line
shows the central moment of the peak at the beginning of the experiment
and demonstrates that no significant change occurred in the position of
this central moment during the course of the study. The Figure is
reproduced with permission from Ref. [30].

Absorbance (225 nm)
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Figure 3-2.

Typical frontal analysis chromatograms obtained when R-propranolol was
applied to a 100 mm × 2.1 mm i.d. LDL column at concentrations of 0.5,
1, 5, 8, 10, 18, or 25 µM. The chromatograms were obtained at a flow rate
of 1.0 mL/min and 27 ºC in the presence of 0.067 M phosphate buffer, pH
7.4. This Figure is reproduced with permission from Ref. [35].
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Figure 3-3.

Double-reciprocal plots of frontal analysis data obtained for the binding of
R- and S-propranolol to a 100 mm × 2.1 mm i.d. LDL column.
Chromatographic conditions included a flow rate of 1.0 mL/min, a
temperature of 37ºC, and a mobile phase of 0.067 M phosphate buffer, pH
7.4. The best fit line was obtained using data points in the upper region of
this plot, which are designated by the closed squares (■). Data points in
the lower region of this plot (i.e., at higher concentrations propranolol)
showed negative deviations from the linear fit to for R-propranolol but not
S-propranolol and are represented by open squares (□).
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The values of mLapp and the known [D] were further used to prepare nonreciprocal plots to study the R- and S-propranolol interactions with LDL; examples of
such graphs are given in Figure 3-4. These plots were fit to equations representing four
different binding models. The binding models that were used to fit the data are
summarized in Table 1-2 and Eqs. 3-6. One type of interaction that a drug may have with
a lipoprotein is described by site specific binding to apolipoproteins on the surface of
LDL, This type of binding is described by the model involving saturable binding at a
single type of site (Eq. 3) [16-18,20]. A similar model in which the drug undergoes
saturable binding at to multiple locations, as might occur if apolipoproteins contained two
distinct binding regions for the applied drug, was considered in Eq. 6. The possibility of
drug interaction with the hydrophobic core of LDL was also considered. This type of
binding is expected to be non-saturable in nature and is described by Eq. 2 [16-18,20]. A
combination of saturable sites and a group of non-saturable interactions was also
considered in a mixed-mode model (Eq. 5), this type of binding was noted earlier for
various drugs with HDL [17]. Fit quality was examined and compared by using the
correlation coefficients for the fits, the overall residual values, and the distribution of the
data about the best-fit line for each model. The binding parameters determined for each
model is provided in Tables 3-2 and 3-3.
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Figure 3-4.

Best fit results of plots to various binding models of frontal analysis data
obtained for R-propranolol on an LDL column at 37 oC. The models used
in this analysis were as follows: (a) non-saturable interactions, (b) a single
group of saturable sites, (c) two groups of saturable sites, and (d) a group
of non-saturable interactions plus a group of saturable sites. The insets
show the residual plots for the fit of each model to the experimental data.
These results were obtained in the presence of 0.067 M phosphate buffer,
pH 7.4. The correlation coefficients were as follows: (a) 0.9959, n = 9; (b)
0.9992, n = 9; (c) 0.9998, n = 9; and (d) 0.9998, n = 9. This figure is
adapted with permission from Ref. [30].

(a)

(c)

(b)

(d)
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Table 3-2
Enantiomer

R-Propranolol

R-Propranolol

R-Propranolol

Binding parameters obtained for R-propranolol on a LDL column at various temperaturesa
Binding Model
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable

Temperature

mL1 (mol)

Ka1 (M-1)

mL1 (mol)

Ka1 (M-1)

nKab (M-1)

20 ᵒC

-

-

-

-

3.5 (± 0.1) x 105

20 ᵒC

1.4 (± 0.4) x 10-7

5.3 (± 1.5) x 103

-

-

-

20 ᵒC

9.0 (± 9.7) x 10-10

4.3 (± 6.2) x 105

1.3 (± 9490) x 10-3

0.5 (± 3491)

-

20 ᵒC

9.0 (± 3.2) x 10-10

4.3 (± 3.4) x 105

-

-

3.2 (± 0.1) x 105

27 ᵒC

-

-

-

-

4.3 (± 0.2) x 105

27 ᵒC

6.6 (± 0.1) x 10-8

1.6 (± 0.5) x 104

-

-

-

27 ᵒC

3.0 (± 2.8) x 10-9

4.4 (± 5.2) x 105

7.9 (± 87342) x 10-4

0.8 (± 9313)

-

27 ᵒC

3.0 (± 0.9) x 10-9

4.4 (± 2.7) x 105

-

-

3.5 (± 0.2) x 105

37 ᵒC

-

-

-

-

2.1 (± 0.1) x 105

37 ᵒC

3.8 (± 0.7) x 10-9

1.2 (± 0.3) x 104

-

-

-

37 ᵒC

7.5 (± 5.7) x 10-10

5.2 (± 4.8) x 105

7.0 (± 81917) x 10-4

0.5 (± 5831)

-

37 ᵒC

7.5 (± 1.5) x 10-10

5.2 (± 2.3) x 105

-

-

1.9 (± 0.1) x 105

a

The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.

b
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The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of LDL in the column. This latter value was
obtained by using the protein content of the LDL support, using a typical protein content for LDL of 25% (w/w), and an average molar mass for LDL of 2.3  106 g/mol.
The best fit model is represented in bold.
This table is adapted with permission from Ref. [30].

Table 3-3
Enantiomer

S-Propranolol

S-Propranolol

S-Propranolol

Binding parameters obtained for S-propranolol on a LDL column at various temperaturesa
Binding Model
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable

Temperature

mL1 (mol)

Ka1 (M-1)

mL1 (mol)

Ka1 (M-1)

nKab (M-1)

20 ᵒC

-

-

-

-

3.2 (± 0.1) x 105

20 ᵒC

2.0 (± 1.8) x 10-7

3.2 (± 3.1) x 103

-

-

-

20 ᵒC

0.1 (± 6.3) x 10-5

0.1 (± 4.5) x 105

2.0 (± 96665940)
x 10-4

0.2 (± 6848026)

-

20 ᵒC

0.1 (± 1.3) x 10-5

0.1 (± 2.0) x 105

-

-

5.4 (± 1294) x 104

27 ᵒC

-

-

-

-

2.8 (± 0.1) x 105

27 ᵒC

4.6 (± 4.5) x 10-7

1.2 (± 1.2) x 103

-

-

-

27 ᵒC

4.9 (± 2636) x 10-9

0.1 (± 3.3) x 106

8.2 (± 3776061)
x 10-4

0.6 (± 268838)

-

27 ᵒC

0.7 (± 6.0) x 10-7

0.6 (± 4.6) x 105

-

-

2.7 (± 0.5) x 105

37 ᵒC

-

-

-

-

2.7 (± 0.2) x 105

37 ᵒC

2.6 (± 2.4) x 10-7

2.0 (± 1.9) x 103

-

-

-

37 ᵒC

6.7 (± 2398) x 10-9

0.1 (± 2.4) x 106

7.6 (± 4477418)
x 10-4

0.6 (± 318741)

-

37 ᵒC

0.1 (± 1.6) x 10-7

0.2 (± 2.3) x 105

-

-

2.2 (± 5.4) x 104

a

The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.

b
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The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of LDL in the column. This latter value was
obtained by using the protein content of the LDL support, using a typical protein content for LDL of 25% (w/w), and an average molar mass for LDL of 2.3  106 g/mol.
The best fit model is represented in bold.
This table is adapted with permission from Ref. [30].
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The overall binding between R-Propranolol and the immobilized LDL was the
result of multiple types of interactions. This was confirmed through a comparison of the
various binding models in Figure 3-4(a-d). The mixed-mode binding model involving
both saturable sites and non-saturable binding generated the best fit for the interactions of
LDL with R-Propranolol.

It should be noted that the mixed-mode model for a

combination of saturable and non-saturable interactions (see Figure 3-4(d)) resulted in the
same correlation coefficient and residual plot as the two-site saturable model (see Figure
5(c)). However, the precisions obtained for the best-fit equilibrium constants obtained
for saturable/non-saturable were much tighter than those obtained for the two-site
saturable model (refer to the standard deviations listed in Table 3-2 for Ka1, mL1 and nKa
in this model versus those values listed for the best-fit parameters in a model based on
two groups of saturable sites). As with the HDL studies, the apparent similarities in these
two fits is explained by the equations for the two-site saturable model approaches that of
a model based on saturable/non-saturable interactions. As shown in Table 1-2, as the
term Ka2[D] in the denominator of Eq. 6 becomes much less than one, the term for the
second interaction becomes mathematically equivalent to the non-saturable term in Eq. 5.
This situation occurs in the fit of the two-site saturable model to the data obtained for
binding between R-propranolol and LDL and explains the large uncertainly values that
resulted. Considering that both models are actually describing the same overall model
where there was a relatively high affinity saturable site and lower affinity, essentially
non-saturable binding also explains why the residual plots in Figures 3-4(c-d) are so
similar.
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Similar interactions were predicted between S-propranolol and LDL, as these
evaluations indicated that binding by this enantiomer gave the best fit with a model for a
single type, non-saturable interaction. The fitting of frontal analysis data for Spropranolol/LDL interactions using the four models presented in Table 1-2 resulted in
very similar fits. Specifically, the four models yielded essentially the same correlation
coefficient and residual plot (i.e., values for r greater than 0.9985). However, the best-fit
equilibrium constants for models other than the one non-saturable interaction model had
large variability in their values (refer to the standard deviations listed in Table 3-3 for
estimated equilibrium constants and binding capacities of these models versus the values
listed for nKa in a model based on only non-saturable binding). This is due to the fact
that Eqs. 4-6 in Table 1-2 representing one-site saturable binding, two-site saturable
binding, and the mixed-mode binding all approach Eq. 3 for a system containing only
non-saturable interactions. This latter situation is realized when Ka1[D] and/or Ka2[D]
become much smaller than one in the denominators of Eqs. 4-6 and as the term for sitespecific binding in Eq. 3 becomes much smaller than the term for non-saturable
interactions. Based on the analysis of these binding models, the data revealed that at all
of the temperatures examined S-propranolol gave the best-fit with a non-saturable model.
This supports the conclusion reached during the evaluation of double-reciprocal plots of
1/mLapp versus 1/[D] that only a single type of interaction was present between Spropranolol and LDL.

Equilibrium binding constants and temperature studies
The best-fit results obtained for R- and S-propranolol with LDL at all
temperatures that were evaluated in this report are summarized in Tables 3-2 and 3-3.
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The saturable interaction between R-propranolol and LDL had an association equilibrium
constant (Ka1) of 5.2 (± 2.3)  105 M-1 at 37 ºC, which is indicative of relatively high
affinity binding. This binding was probably occurring between the drug and
apolipoprotein B100 (apoB100) on LDL. This hypothesis is supported by a comparison
of the measured binding capacity of LDL to the moles of apoB100 that were determined
to be present in the LDL column during the BCA protein assay. The total moles of
binding sites determined using the frontal analysis data was consistently in the range of
0.7 to 3.0 nmol for R-propranolol between 20 °C and 37 °C (average, 1.6 nmol). This
value is in agreement with the amount of LDL that was estimated to be present in the
column (i.e., 1.9 (± 0.1) nmol) using the BCA column, where each LDL particle typically
contains one apoB100 molecule [7]. Saturable binding of propranolol with
apolipoproteins of HDL was also suggested in Chapter 2.
The second type of interaction that occurred for R-propranolol with LDL was
non-saturable in nature and had an overall affinity (nKa) of 1.9 (± 0.1)  105 M-1 at 37 ºC.
This interaction likely occurs between R-propranolol and phospholipids or the non-polar
core of LDL. The presence of non-saturable interactions has been suggested in previous
work examining the binding of R/S-propranolol and other drugs with both LDL and HDL
[16,17,20]. An approximately equivalent overall affinity of 2.7 (± 0.2)  105 M-1 was
obtained in this study for the non-saturable binding of S-propranolol with LDL at 37 ºC.
The impact that temperature had on the interactions that occur between R- and Spropranolol and LDL was also examined. The results obtained during the best fit
analysis did not reveal a significant effect on the equilibrium constants, binding
capacities, or binding models that were obtained for R- and S-propranolol with LDL
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between 20 oC and 37 oC. At the temperatures employed in this study, the binding
models listed in Table 3-2 and Table 3-3 gave correlation coefficients for R- and Spropranolol that were greater than 0.998. The Ka1 values measured for the saturable
binding of R-propranolol with LDL varied from only 4.3-5.2  105 M-1 over this
temperature range. The nKa values for non-saturable binding by R-propranolol with LDL
were in the range of 1.9-3.5  105 M-1, while the nKa values for the S-enantiomer were in
a similar range of 2.7-3.2  105 M-1 under the given temperature conditions.
The nKa value obtained for drug binding by LDL is expected to be larger than that
obtained by HDL due to the fact that LDL has a much larger portion of hydrophobic
components (i.e., cholesterol and triacylglycerides) than HDL [7-9,17]. Previous studies
that compared drug binding by LDL and HDL have confirmed this trend [16,17]. The
nKa values measured for the non-saturable interaction of R- and S-propranolol with LDL
were approximately five- to nine-fold higher than values of 3.7-4.1  104 M-1 that were
measured at pH 7.4 and between 4 °C and 37 °C for the same type of interaction of these
enantiomers with immobilized HDL [20]. Despite the fact that LDL and HDL contain
different types of apolipoproteins [7], the Ka1 values measured for the saturable binding
of R-propranolol with LDL were similar to values of 1.4-1.9  105 M-1 that were
estimated for saturable binding of the same solute with HDL [20]. In addition, the range
of Ka1 and nKa values obtained during this study agreed with the previously reported
range of 1-4  105 M-1 in overall affinities obtained with soluble LDL at pH 7.4 and 25
°C to 37 °C for R- and S-propranolol when using only a non-saturable binding model
[16,17].
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In this study, the binding of propranolol to LDL was determined to be
stereoselective. This is supported by the fact that R- and S-propranolol consistently
followed different binding models at the temperatures employed in this report (i.e. 20 ᵒC
to 37 ᵒC). This stereoselectivity arises from the observation that only the R-enantiomer
had significant saturable binding to LDL under the conditions of this study. This
stereoselective binding likely occurred with apoB100. Stereoselective interactions were
not noted in earlier studies with HDL, where both R- and S-propranolol were found to
undergo two types of interactions, i.e., a saturable interaction that probably involved
apolipoproteins and a non-saturable, partition-like interaction [20]. Prior work examining
the binding of propranolol with LDL either used a racemic preparation of the drug [16] or
did not note significant, stereoselective interactions when using only a non-saturable
binding model [17]. Due to the similarity in the binding constants that were determined
in this study for the saturable and/or non-saturable interactions of R- and S-propranolol
with LDL, it is not surprising these interactions were not previously noted.
HDL and LDL contain different types of apolipoproteins (see Table 1-1),
explaining why stereoselective binding occurred for R- and S-propranolol with LDL but
not in prior work with HDL that also used a mixed-mode model [20]. For instance, LDL
contains only one apolipoprotein molecule per particle (i.e., ApoB100) while HDL may
contain up to 5-6 apolipoproteins per particle [7]. The apolipoproteins associated with
HDL (i.e. ApoA1, ApoA2, ApoE and ApoC) are not associated with LDL [7].

The

ability of apoB100 to specifically bind to hormones and drug-like compounds has been
previously noted for a number of steroids, including 17-β-estradiol, testosterone, and
progesterone [31-33]. However, the results of this study are believed to be the first
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instance in which stereoselective interactions with apoB100, apolipoproteins, or
lipoprotein particles have been observed.

CONCLUSIONS
In this chapter, LDL was immobilized in chromatographic columns and used in
drug binding studies. Both enantiomers of propranolol were used individually as solutes
for this work. Stability studies demonstrated that an LDL column was suitable for use
over at least 60 h of continuous operation without any significant loss of retention for Rpropranolol. The use of columns containing immobilized LDL in frontal analysis studies
indicated that propranolol had two distinct types of interactions with LDL. Each of these
drug enantiomers underwent non-saturable interactions with LDL, which was most likely
due to interactions with the phospholipids or the non-polar core of LDL. The overall
affinities for the non-saturable interactions of R- and S-propranolol were similar and in
the range of 1.9-3.5  105 M-1 at 20 °C to 37 oC. A second, saturable type of binding was
observed only with R-propranolol. This saturable interaction had an association
equilibrium constant in the range of 4.3-5.2  105 M-1 between 20 °C to 37 ºC. These
results were in good agreement with binding constants that have been reported for
propranolol when using a similar mixed-mode model for immobilized HDL [20] and with
the overall affinities that have been measured for soluble LDL based on a non-saturable
model [16,17].
Stereoselectivity of the binding was indicated by the differences between the
binding of R- and S-propranolol to LDL, particularly with regard to the presence or
absence of measurable saturable interactions. Chiral selectivity is well known to occur as
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drugs bind to serum proteins such as HSA and AGP, however, this report is the first
known example of chiral selectivity for LDL or any other lipoprotein [3,4,34,35]. This
stereoselectivity was due to the binding of R-propranolol to apoB100, as suggested by the
stoichiometry of the saturable interactions for R-propranolol with LDL. To our
knowledge, this work is also the first example of chiral interactions that involve the
binding of a drug with an apolipoprotein. Similar HPAC columns could be used for
zonal elution and competition studies [3,4,25,26] to further examine the interactions of Rand S-propranolol on LDL.. Future work could also focus on the evaluation Rpropranolol binding in the presence of other compounds known to bind to apoB100 (e.g.,
testosterone, 17-β-estradiol, and progesterone) [31-33].
This report illustrated the feasibility of utilizing HPAC as a tool for the
characterization of mixed-mode interactions that involve LDL and related binding agents.
As was observed in previous work with HDL columns [20], this approach can provide
analysis times of only a few minutes per run (e.g., see examples in Figures 3-1). The
LDL columns developed in this report were also sufficiently stable for use in hundreds of
experiments, which significantly reduces the amount of ligand required currently needed
for alternative methods. . For example, the CE/frontal analysis studies in Ref. [17]
required150 nmol LDL per analysis. In contrast, one HPAC column used for this work
contained 350 nmol LDL and was applied to more than 160 experiments, which averages
to less than 2.2 nmol LDL per analysis. The ability to utilize the same LDL column for
multiple studies made it possible to minimize run-to-run variability.. Furthermore, the
ability to utilize these immobilized lipoprotein columns with standard HPLC detectors
yields lower limits of detection during the binding studies [3,4,20]. When combined,
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these advantages enabled the rapid collection of precise data over a wide range of drug
concentrations and the identification of mixed-mode interactions and stereoselective
binding between LDL and R- or S-propranolol. These same features should make future
studies examining the binding of other drugs and solutes with LDL or alternative
lipoproteins using HPAC columns and methods successful.
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CHAPTER FOUR
ANALYSIS OF DRUG INTERACTIONS WITH VERY LOW DENSITY
LIPOPROTEIN BY HIGH PERFORMANCE AFFINITY CHROMATOGRAPHY

Portions of this chapter have previously appeared in M.R. Sobansky, and D.S. Hage,
“Analysis of drug interactions with very low density lipoprotein by high-performance
affinity chromatography", Analytical and Bioanalytical Chemistry, 2014, 406, 62036211.

INTRODUCTION
As discussed in Chapter 1, the binding of drugs and other analytes with serum
proteins and lipoproteins can influence the activity, toxicity, delivery and
pharmacokinetics of such agents in the human body [1-8]. Information about the type
and strength of these interactions can be useful in determining how drugs are distributed
after their administration and is of potential interest for the design of personalized dosage
regimens [4,8]. These interactions may be stereoselective due to the inherent chirality of
proteins thereby potentially influencing drug safety and efficacy [9-13].
The basic and chiral drug propranolol (see Chapter 1) is known to bind several
serum proteins and lipoproteins, including very low density lipoprotein (VLDL) [14-17].
The binding of propranolol by VLDL has been examined with methods based on
equilibrium dialysis in previous studies, which revealed a non-saturable interaction [14].
The properties of propranolol (see Chapter 1) and the results of previous studies between
lipoproteins and propranolol (see Chapters 2 and 3) lead to the hypothesis that multiple
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types of interactions are present. These interactions may include specific interactions
with fixed binding regions, interactions with surface phospholipids, or partitioning into
the non-polar core of a lipoprotein [7,18-25].
In this chapter, the HPAC methods described previously were modified and
extended to the study of drug interactions with VLDL. The R- and S-enantiomers of
propranolol served as model drugs for this work because propranolol is known to interact
with VLDL and estimates of the binding constants for this system have been reported for
soluble VLDL (i.e., based on the use of a non-saturable binding model and racemic
propranolol) [14]. These interactions were examined in the research described herein by
preparing and employing columns containing VLDL immobilized to silica and utilizing
the columns in frontal analysis experiments. These experiments were completed to
determine the types and strength of interactions that occur between VLDL and R- and Spropranolol at various temperatures. The results obtained were compared to data
obtained using equilibrium dialysis and soluble samples of VLDL [14]. The binding
constants determined were then evaluated against previous results obtained for the same
drugs with HDL and LDL [10,14-17,26]. These experiments are expected to provide a
more complete description of the binding mechanisms between R- and S-propranolol with
VLDL in vivo. In addition, the results of this study should indicate the possible
advantages in using HPAC to examine drug binding with lipoproteins.
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EXPERIMENTAL
Reagents
The R- and S-propranolol and human VLDL (catalog number L7527, lot no.
036K1143) were obtained from Sigma (St. Louis, MO, USA). Nucleosil Si-1000 silica
(1000 Å pore size) with a 7 µm particle diameter was obtained from Macherey Nagel
(Düren, Germany). Bicinchoninic acid (BCA) protein assay reagents were purchased
from Pierce (Rockford, IL, USA). All other chemicals were of the highest grades
available and all solutions used in chromatographic studies were prepared using water
from a Nanopure purification system (Barnstead, Dubuque, IA, USA) filtered using
Osmonics 0.22 µm nylon filters from Fisher Scientific (Pittsburgh, PA, USA).

Apparatus
The chromatographic system utilized in these studies consisted of a Vici F60-AL
injection valve (Houston, TX, USA), an Eppendorf CH-500 column heater (Hauppauge,
NY, USA), two 510 Waters HPLC pumps (Milford, MA, USA), and a Waters 2487
UV/Vis absorbance detector. Chromatograms were collected using Waters Empower
software and processed using programs based on Labview 5.1 (National Instruments,
Austin, TX, USA). The chromatographic columns were packed into 100 mm × 2.1 mm
i.d. stainless steel columns by using a slurry packer from Alltech (Deerfield, IL, USA).
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Table 4-1

Comparison of binding parameters for R- and S-propranolol with various lipoproteins at pH 7.4 and 37 oC

Lipoprotein

Type of drug

Binding model [Ref.]a

mL1 (mol)

Ka1 (M-1)

nKa (M-1)

R-Propranolol

Saturable site + non-saturable binding [31]

2.2 (± 0.7)  10-9

1.9 (± 0.8)  105

4.1 (± 0.3)  104

S-Propranolol

Saturable site + non-saturable binding [31]

4.5 (± 0.2)  10-9

1.1 (± 0.1)  105

3.7 (± 0.2)  104

R/S-Propranolol

Non-saturable binding [14]

N/A

N/A

1.60 (± 0.14)  104

R-Propranolol

Saturable site + non-saturable binding [10]

7.5 (± 1.5)  10-10

5.2 (± 2.3)  105

1.9 (± 0.1)  105

S-Propranolol

Non-saturable binding [10]

N/A

N/A

2.7 (± 0.2)  105

R/S-Propranolol

Non-saturable binding [14]

N/A

N/A

1.76 (± 0.01)  105

R/S-Propranolol

Non-saturable binding [14]

N/A

N/A

2.87 (± 0.28)  105

High density
lipoprotein (HDL)

Low density
lipoprotein (LDL)

Very low density
lipoprotein (VLDL)

a

Ref. [14] utilized soluble lipoproteins, while Refs. [10] and [26] used immobilized lipoproteins.
This table is adapted with permission from Ref. [28].
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Preparation of VLDL silica
The VLDL was immobilized onto HPLC silica using the Schiff base method
under conditions similar to those described in Chapters 2 and 3 for HDL and LDL. The
first step in the preparation of immobilized VLDL was to convert the Nucleosil Si-1000
silica to diol-bonded silica, as previously described [27]. Following preparation of this
support, a portion of the diol-bonded silica was utilized as a control support. As
prescribed in the Schiff base method, the diol-bonded silica was converted into an
aldehyde-activated form by placing 0.9 g of this support into 15 mL of a 90:10 (v/v)
mixture of acetic acid and water that contained 0.9 g periodic acid. This mixture was
sonicated under vacuum for 10 min and subsequently shaken at room temperature in the
dark for 1 h. The resulting aldehyde-activated silica was washed five times with water
and three times with 0.10 M potassium phosphate buffer, pH 6.0.
Next, a 0.45 g portion of the aldehyde-activated support was placed into 5 mL of,
0.10 M potassium phosphate buffer, pH 6.0. This suspension was sonicated for 5 min
under vacuum and a 5 mg portion of sodium cyanoborohydride was added. The sodium
cyanoborohydride functioned to reduce Schiff bases that form between the aldehyde
support and primary amine groups on a ligand. This reduction step was followed by the
addition of 1 mg VLDL. The mixture was shaken gently at 4 ºC while protected from
light for 8 days. The resulting VLDL support was washed four times with 0.067 M
potassium phosphate buffer, pH 7.4. Next, 2 mL of a 1.5 mg/mL sodium borohydride
0.067 M potassium phosphate buffer, pH 7.4, was added slowly to the VLDL support
slurry to reduce any remaining aldehyde groups that were still present on the silica. This
mixture was shaken for 90 min at room temperature and was washed six times with 0.067
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M potassium phosphate buffer, pH 7.4. The final VLDL immobilized support stored in
the same buffer at 4 ºC until use.
The VLDL support protein content was determined using a BCA protein assay
and bovine serum albumin as the protein standard; a method previously employed with
supports containing HDL and LDL [10,31]. The samples and standards used in this assay
were prepared in pH 7.4, 0.067 M potassium phosphate buffer, with the VLDL silica
samples were examined in triplicate, using diol-bonded silica as the blank. Sample and
standard solutions were filtered through a 0.22 m nylon filter to remove particulates
prior to determining absorbance readings for this assay.

Chromatographic studies
The VLDL silica or control support were downward slurry packed at 3500 psi
into separate 100 mm  2.1 mm i.d. stainless steel columns using 0.067 M potassium
phosphate buffer, pH 7.4, as the packing solution. The packed columns were
subsequently stored in this pH 7.4 buffer at 4°C when not in use. The VLDL column or
control column was equilibrated with the same buffer at the specified temperature before
each chromatographic experiment. All mobile phases were filtered through an Osmonics
0.22 µm nylon filter and vacuum degassed immediately prior to use. A wavelength of
225 nm was used to monitor the elution of R- and S-propranolol.
The stability of the immobilized VLDL columns was examined through zonal
elution studies on the VLDL supports. This evaluation was performed by conducting
replicate 20 µL injections of a 25 mM solution of R-propranolol dissolved in 0.067 M
potassium phosphate buffer, pH 7.4, on the columns. A mobile phase of, 0.067 M
potassium phosphate buffer, pH 7.4, was applied at 1.0 mL/min and 37°C for 30 hours in
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these studies. The retention time for each peak was determined using Waters Empower 2
Software (Waters Corporations, Milford Massachusetts).
Frontal analysis studies were conducted using the VLDL control column to
examine both R- and S-propranolol. The frontal analysis studies were carried out at 20
ºC, 27 ºC or 37 ºC and a flow rate of 0.5 mL/min. These conditions were shown in
previous studies with HDL and LDL columns to be suitable for drug binding studies and
to have no significant impact on the measured binding capacities or equilibrium constants
[10,26]. The mobile phase for sample application and elution was 0.067 M potassium
phosphate buffer, pH 7.4. Nine solutions containing 0.2-25 µM of R- or S-propranolol
were applied to each column in triplicate. The results were integrated using programs
written in Labview 5.1 to determine the moles of drug that were required to reach the
mean breakthrough time at a given concentration of the applied drug [3]. The control
column breakthrough times were subtracted from those measured at the same drug
concentration on a VLDL column to correct for the void time and non-specific binding of
propranolol to the support. This process was also described in previous chapters for
studies involving HDL and LDL columns. The degree of non-specific binding was
typically comprised 7-15% of the total breakthrough time for R- and S-propranolol on the
VLDL column. The frontal analysis results were fit to the binding models described in
Table 1-2 using non-linear regression and Origin 9.1 software (OriginLab, Northampton
Massachusetts).
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RESULTS AND DISCUSSION
General properties of VLDL support
A protein assay was used to determine the quantity of lipoprotein that was
immobilized on the VLDL support; this was combined with the column dimensions to
ascertain the moles of lipoprotein in the HPAC column. The VLDL support was
determined to contain 1.23 (± 0.03) mg apolipoprotein per gram silica. This result
equates to 15.4 (± 0.4) mg or 2.05 (± 0.05) nmol of VLDL per gram silica, when using an
average molar mass of 7.5  106 g/mol for VLDL [14] and a typical apolipoprotein
content for VLDL of 8% (w/w) [24]. When taking the column dimensions and silica
packing density into account, a total of 0.27 nmol of VLDL was estimated to be in each
HPAC column. This amount of immobilized VLDL (15.4 mg, or 2.05 nmol, per gram
silica) was lower than the 28 mg (12 nmol) LDL per gram silica and 68 mg (380 nmol)
HDL per gram silica that were obtained with the other lipoproteins in Chapters 2 and 3.
However, as will be seen later, this VLDL content was still in a range that was suitable
for drug binding studies.
The lower lipoprotein content observed for the VLDL support when compared to
prior LDL or HDL supports was the result of several factors. First, VLDL has a larger
diameter than either lipoprotein previously examined (typical diameter: VLDL, 30-80
nm; LDL, 18-25 nm; HDL, 5-12 nm) [19]. This larger size mandates that a support with
a larger pore size, and a lower surface area, is used to immobilize VLDL. Silica with a
pore size of 1000 Å (100 nm) was used to immobilize VLDL A support with a 500 Å
pore size was used in LDL studies, while a 300 Å support was used in HDL studies
[10,26]. In addition to lipoprotein diameter, the extent of immobilization was impacted
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by the greater expense and relatively low solubility of VLDL. These factors resulted in a
smaller amount of this lipoprotein being combined with the support during the
immobilization process (i.e., a ratio of 2.2 mg VLDL per gram silica in the starting
mixture, compared with 16.7 mg LDL per gram silica or 100 mg HDL per gram silica).
VLDL column stability was examined using both zonal elution and frontal
analysis studies. First, repeated injections of R-propranolol were made onto a VLDL
column under controlled temperature and flow rate conditions. A reproducible retention
time for R-propranolol occurred over the course of several weeks using an equivalent of
30 h of operation at a flow rate of 1 mL/min (i.e., at least 2.8 L of mobile phase, or 9.3 
103 column volumes). During these zonal elution experiments R-propranolol had an
average retention time of 3.2 (± 0.3) min and an average retention factor of 9.5 (± 0.9).
Frontal analysis studies were conducted on a fresh VLDL column and demonstrated
similar stability and reproducibility over the course of several months. These studies
included more than 160 measurements and involved the application of at least 3.4 L of
the mobile phase (i.e., 1.13  104 column volumes). The zonal elution and frontal
analysis data indicated that the VLDL support had similar stability to that observed for
HDL and LDL supports [10,26]. These studies also indicated that the VLDL support was
suitable for use in long-term studies involving multiple drug binding measurements. The
stability of these columns and the relatively small amount of immobilized lipoprotein
within a column meant that the average amount of VLDL per experiment is extremely
low. This is exemplified in this study by the use of an HPAC column containing 0.27
nmol VLDL for 160 experiments, which equates to an average of 1.7 pmol VLDL per
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sample application. This level of lipoprotein is significantly less than required to perform
other methods of analysis (e.g. equilibrium dialysis or CE) [14-17].

Examination of binding mechanisms for R- and S-propranolol with VLDL
Frontal analysis was used to examine the binding of R- or S-propranolol to the
VLDL support. Typical breakthrough curves obtained on a VLDL column are shown in
Figure 4-1. The mean position of the breakthrough curves appeared between 2 and 7
minutes of sample application, depending on the concentration of the applied analyte.
The precision of these measurements was typically within the range of ± 1 to 2%. These
breakthrough times were similar to those obtained with LDL columns of the same size
[26], but were roughly twice as long as the times needed with HDL columns that were
half this size [10]. The individual run times in these studies were shorter. The analysis
time of 16 min previously reported when using CE to examine drug interactions with
lipoproteins [15] and was much shorter than the six hours that have been used to perform
drug-lipoprotein binding studies by equilibrium dialysis [14].
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Figure 4-1.

Typical frontal analysis results obtained for the application of various
concentrations of R-propranolol solutions to a 100 mm × 2.1 mm i.d.
VLDL column at 0.5 mL/min and 37ºC in the presence of 0.067 M
phosphate buffer, pH 7.4. This Figure is reproduced with permission from
Ref. [28].
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The moles of drug required to reach the mean position of each breakthrough curve
(mLapp) was determined by integration of the frontal analysis curves. The determined
mLapp values were then used in conjunction with the known concentration of the applied
drug ([D]) to generate a double-reciprocal plot of 1/mLapp versus 1/[D]. Examples of the
resulting double-reciprocal plots are shown in Figure 4-2. As described in previous
chapters, the presence of only one binding mechanism for the drug on the immobilized
ligand is expected to result in a linear relationship for a system with relatively fast
association and dissociation kinetics compared to the time scale of the experiment [8].
When multiple binding mechanisms are present, this type of plot should yield deviations
from a linear response at large drug concentrations (i.e. low values of 1/[D]) [8]. Each of
the double-reciprocal plots produced for R- and S-propranolol at 20 ºC, 27 ºC and 37 ºC
resulted in these negative deviations at high analyte concentrations. Therefore, the
double-reciprocal plots are indicative of the presence of multiple binding mechanisms
between R- or S-propranolol and VLDL. This is consistent with what has been
previously observed between R- or S-propranolol with HDL [26], and for R-propranolol
with LDL [10].
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Figure 4-2.

Double-reciprocal plots obtained in frontal analysis studies examining the
binding of (a) R-propranolol and (b) S-propranolol to a 100 mm  2.1 i.d.
VLDL column at 37oC and in the presence of pH 7.4, 0.067 M phosphate
buffer. The linear fits that are shown were obtained using data points in
the upper region of this plot, which are designated by the closed squares
(■) and cover R- or S-propranolol concentrations that range from 0.2 to 4
M. Data points in the lower regions of these plots (i.e., at higher
concentrations of R- or S-propranolol) showed negative deviations from
the linear fit to the upper data points and are represented by open squares
(□). Expanded views of the lower regions to the left of these graphs are
provided in the insets. This figure is reproduced with permission from
Ref. [28].
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Following the analysis of the frontal analysis data using double-reciprocal plots,
the breakthrough curves were examined in more detail using the binding models
described in Table 1-2. The first step in these examinations was to prepare non-linear
plots of mLapp versus [D] (see examples in Figure 4-3). Next, the fit of each of the four
binding models was tested for use in describing the interactions between R- or Spropranolol and VLDL. Several previous studies based on equilibrium dialysis or CE
have used partitioning to describe the interactions between propranolol and other drugs
with lipoproteins [10,14-17,26]. This binding mechanism was also considered in this
study using the single non-saturable interaction model. A second type of interaction that
may occur is site-specific and saturable binding, as has been noted for R- or Spropranolol with HDL and for R-propranolol with LDL, was considered in describing the
interactions with VLDL [10,26]. The double-reciprocal plots indicated that the system
under study had the possibility of multiple site-specific binding locations, which was
considered by using a model based on two groups of saturable sites [10,26]. Finally, a
mixed-mode model was examined in which a single, saturable site and a group of nonsaturable interactions were present. The goodness of fit for each model examined was
evaluated using the correlation coefficients, residual values, and the distribution of the
data about the best-fit line. The corresponding association equilibrium constants, binding
capacities, or global affinity constants that were obtained for each model are summarized
in the Table 4-2 and Table 4-3.
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Figure 4-3.

Fit of various binding models to frontal analysis data obtained for Rpropranolol on a VLDL column at 37 oC and pH 7.4. The models used in
this analysis were as follows: (a) non-saturable interactions, (b) a single
group of saturable sites, (c) two separate groups of saturable sites, and (d)
a group of non-saturable interactions plus a group of saturable sites. The
insets show the residual plots for the fit of each model to the experimental
data. The correlation coefficients were as follows (n = 9): (a) 0.9570, (b)
0.9992, (c) 0.9994, and (d) 0.9998. This figure is reproduced with
permission from Ref. [28].
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The non-saturable interaction model and the model based on a single group of
saturable sites (both models that used a single type of interaction) gave reasonably good
correlation coefficients (i.e., 0.9570 and 0.9992 respectively) when fit to the frontal
analysis data. Despite these reasonable correlation coefficients, the residual plots for the
non-saturable model failed to yield a non-random pattern of data points about the best-fit
line, as demonstrated by the inset in Figure 4-3(a). Furthermore, both of the single
interaction models gave lower correlation coefficients than the two-site or mixed-mode
models for the same data. A lower sum of the squares for the residuals (e.g., 0.017-1.59
× 10-17 for the non-saturable or one-site saturable model vs. 0.86-6.01 × 10-19 for the twosite or mixed-mode models) was also obtained for the plots describing multiple
interactions. These results support the conclusion drawn from the double-reciprocal
plots, i.e., that multiple types of interactions were occurring between R- or S-propranolol
and VLDL.
A more thorough evaluation of the multi-site interaction models in Figure 4-3 (cd) indicated that similar fits and residual plots were generated when using a two-site
saturable model or a mixed-mode model based on one set of saturable sites plus a nonsaturable interaction. Despite these similarities, the correlation coefficient obtained for
the mixed-mode model was slightly higher than the value for the two-site saturable model
(r = 0.9998 vs. 0.9994). Furthermore, the equilibrium constants provided by the mixedmode model were much more precise than those obtained for the two-site saturable
model. The equilibrium binding constants and corresponding precision are listed in
Table 4-2 and Table 4-3. All of this information indicated that the mixed-mode model
provides the best description of the interactions between R- or S-propranolol and VLDL.
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The same conclusion was reached at all of the temperatures evaluated through the course
of this study. These results were consistent with the binding mechanisms that were
proposed for the binding by R- and S-propranolol with HDL and for R-propranolol with
LDL in Chapters 2 and 3.

Determination of equilibrium constants and number of interaction sites
Following determination of the proper model to describe the binding of R- and Spropranolol with VLDL, the mixed-mode model was used to provide more details on
these interactions. This evaluation revealed that neither the temperature nor enantiomer
significantly impacts the mixed-mode binding between propranolol and VLDL. One
example of this can be seen in the evaluation of the single-site saturable interactions of Rand S-propranolol with VLDL. The R- enantiomer had an association equilibrium
constant (Ka1) of 7.0 (± 2.3)  104 M-1 at 37 ºC while the interaction between Spropranolol and VLDL at the same temperature were statistically equivalent (at the 95%
confidence level) for Ka1 of 9.6 (± 2.2)  104 M-1. Furthermore, the Ka1 value for Rpropranolol with VLDL varied from only 7.0 to 9.2  104 M-1 between 20 °C and 37 °C
while the Ka1 for S-propranolol ranged from 4.6 to 9.6  104 M-1 over this temperature
range. For both propranolol enantiomers, no significant variability in Ka1 occurred at the
95% confidence level over this temperature range for most of these values, with the only
exception being a possible decrease in the value obtained for VLDL with S-propranolol at
27 °C. A paired Student’s t-test was used to verify that overall set of values obtained for
the two enantiomers were not significant different at the 95% confidence level.

Table 4-2
Enantiomer

R-Propranolol

R-Propranolol

R-Propranolol

Binding parameters obtained for R-propranolol on a VLDL column at various temperaturesa
Binding Model
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable
Non-saturable
interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + non-saturable

Temperature

mL1 (mol)

Ka1 (M-1)

mL1 (mol)

Ka1 (M-1)

nKab (M-1)

20 ᵒC

-

-

-

-

4.2 (± 0.1) x 106

20 ᵒC

9.8 (± 0.7) x 10-8

1.5 (± 0.1) x 104

-

-

-

20 ᵒC

4.9c x 10-8

1.5 (± 85,000)
x 104

4.9c x 10-8

1.5 (± 85,000)
x 104

-

9.2 (± 4.8)  104

-

-

3.0 (± 0.3)  106

20 ᵒC

1.0 (± 0.5)  10-8

27 ᵒC

-

-

-

-

4.4 (± 0.1) x 105

27 ᵒC

9.7 (± 0.7) x 10-8

1.6 (± 0.1) x 104

-

-

-

27 ᵒC

4.9 (± 7,000,000)
 10-8

1.6 (± 53,000)
 104

4.9 (± 7,000,000)
 10-8

1.6 (± 53,000)
 104

-

27 ᵒC

1.3 (± 0.8)  10-8

7.3 (± 4.3)  104

-

-

2.9 (± 0.5)  106

37 ᵒC

-

-

-

-

2.7 (± 0.1) x 106

37 ᵒC

4.0 (± 0.2) x 10-8

2.9 (± 0.2) x 104

-

-

-

37 ᵒC

7.0 (± 3.7)  10-10

1.2 (± 1.0)  106

4.6 (± 0.3)  10-8

2.1 (± 0.3)  104

-

37 ᵒC

1.3 (± 0.5)  10-8

7.0 (± 2.3)  104

-

-

1.2 (± 0.3)  106

a

The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.

b

The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of LDL in the column. This latter value was
obtained by using the protein content of the LDL support, using a typical protein content for LDL of 25% (w/w), and an average molar mass for LDL of 2.3  106 g/mol.
c
The fitting program (Origin) was not able to generate an estimate of the standard deviation in these cases.
The best fit model is represented in bold.
This table is adapted with permission from Ref. [28].
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Table 4-3
Enantiomer

S-Propranolol

S-Propranolol

S-Propranolol

Binding parameters obtained for S-propranolol on a VLDL column at various temperaturesa
Binding Model
Non-saturable
Interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + nonsaturable
Non-saturable
Interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + nonsaturable
Non-saturable
Interaction
Single group of
saturable sites
Two groups of
saturable sites
Two interactions:
saturable + nonsaturable

Temperature

mL1 (mol)

Ka1 (M-1)

mL1 (mol)

Ka1 (M-1)

nKab (M-1)

20 ᵒC

-

-

-

-

4.3 (± 0.2) x 106

20 ᵒC

8.1 (± 0.5) x 10-8

2.0 (± 0.2) x 104

-

-

-

20 ᵒC

9.5 (± 5.7)  10-10

1.3 (± 1.4)  106

1.0 (± 0.1)  10-7

1.3 (± 0.2)  104

-

20 ᵒC

1.6 (± 0.8)  10-8

6.9 (± 3.4)  104

-

-

2.5 (± 0.5)  106

27 ᵒC

-

-

-

-

4.1 (± 0.2) x 106

27 ᵒC

7.6 (± 0.3) x 10-8

2.0 (± 0.1) x 104

-

-

-

27 ᵒC

2.4 (± 7.7)  10-8

4.7 (± 7.9)  104

9.6 (± 660)  10-7

5.4 (± 390)  102

-

27 ᵒC

2.5 (± 0.9)  10-8

4.6 (± 1.3)  104

-

-

1.8 (± 0.4)  106

37 ᵒC

-

-

-

-

3.5 (± 0.1) x 106

37 ᵒC

8.5 (± 0.9) x 10-8

1.4 (± 0.2) x 104

-

-

-

37 ᵒC

4.3 (± 2,700,000)
 10-8

1.4d  104

4.3 (± 2,700,000)
 10-8

1.4d  104

4.3 (± 2,700,000)
 10-8

37 ᵒC

0.78 (± 0.16)  10-8

9.6 (± 2.2)  104

-

-

2.4 (± 0.6)  106

a

The numbers in parentheses represent a range of ± 1 S.D. All of these results were measured in pH 7.4, 0.067 M potassium phosphate buffer.

b

The value for nKa for a non-saturable interaction was obtained by dividing the best-fit result for mLKa by the estimated moles of LDL in the column. This latter value was
obtained by using the protein content of the LDL support, using a typical protein content for LDL of 25% (w/w), and an average molar mass for LDL of 2.3  106 g/mol.
c
The fitting program (Origin) was not able to generate an estimate of the standard deviation in these cases.
The best fit model is represented in bold.
This table is adapted with permission from Ref. [28].
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The non-linear regression indicated that the VLDL column had an amount of the
saturable binding sites in the range of 7.8 to 25 nmol for R- and S-propranolol at 20 °C to
37 °C (average: R-propranolol = 12 nmol, S-propranolol = 16 nmol). This value is 5.4- to
17-fold larger (average, 9.7-fold larger) than the moles of VLDL particles that were
estimated to be present in the column using the BCA protein assay. This result is
expected based upon work with HDL and LDL that demonstrated saturable binding
occurs with apolipoproteins [10,26], which can have many copies present on a large
lipoprotein particle such as VLDL [19].
Several apolipoproteins may be present on a single copy of VLDL. The
apolipoproteins present on VLDL may include B-100, C-I, C-II, C-III, and/or E [7].
Most of these apolipoproteins are also found in HDL or LDL, with LDL containing
apolipoprotein B-100 and HDL comprised of apolipoproteins A-I, A-II, C-I, C-II, C-III,
D, and E [7]. The Ka1 values that are listed in Table 4-2 and Table 4-3 for R- and Spropranolol with VLDL are similar to or only slightly lower than the values of 1.1-1.9 
105 M-1 measured under the same pH and temperature conditions for the saturable
binding by propranolol with HDL (e.g., see results in Table 4-1) [31]. This suggests that
apolipoproteins responsible for the saturable interactions with propranolol are common
between HDL and VLDL (e.g., apolipoproteins C-I, C-II, C-III, and E) [7].
Although apolipoprotein is common between VLDL and LDL, the
stereoselectivity that was described in Chapter 3 for the binding of R- and S-propranolol
to LDL (and proposed to be due to apolipoprotein B-100) was not detected in studies
with VLDL. Furthermore, the Ka1 values that have been measured for R-propranolol with
LDL are 4.6- to 11.3 times higher than the values for VLDL under the same pH and
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temperature conditions [10]. The lower binding strength and lack of stereoselectivity
with VLDL indicates that apolipoprotein B-100 is probably not a significant source of the
saturable binding compared to that for VLDL and propranolol. The presence of a greater
amount of apolipoproteins other than B-100 in VLDL may be responsible for this
phenomenon. Alternatively, the presence of these other apolipoproteins may impact the
accessibility and/or conformation of apolipoprotein B-100 in the region at which the
stereoselective binding of propranolol occurs with LDL. The latter possibility is
supported by other reports that have shown that the presence of other apolipoproteins
(e.g., apolipoproteins C and E) impacts the ability of apolipoprotein B-100 to bind to
enzymes and cell surface receptors through protein-protein interactions [29].
Non-saturable binding was the second mechanism that made up the total
interaction between R- and S-propranolol with VLDL. This interaction had an overall
affinity (nKa) at pH 7.4 and 37 ºC of 1.2 (± 0.3)  106 M-1 for R-propranolol and 2.4 (±
0.6)  106 M-1 for S-propranolol. The overall affinity values ranged from 1.2 to 3.0  106
M-1 for R-propranolol and 1.8 to 2.5  106 M-1 for S-propranolol at temperatures between
20 ºC and 37 ºC. There was no significant difference in the overall set of values obtained
for the two enantiomers, as determined by using a paired Student’s t-test at the 95%
confidence level. This type of interaction has been suggested in previous work in this
dissertation to describe the partitioning of R- and S-propranolol or other drugs into the
non-polar core of a lipoprotein, or an interaction with phospholipids on the surface
[10,14,15,26]. The overall affinity values for the non-saturable binding of R- and Spropranolol with VLDL were approximately 30- to 200-times higher than the values of
1.6-4.1  104 M-1 that have been measured at pH 7.4 and between 4 °C and 37 °C for the
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same type of interaction of these enantiomers with HDL [14,15,26]. Furthermore, these
values were 3- to 17-times larger than nKa values that have been obtained for R- and Spropranolol with LDL [10,14,15]. The difference in nKa values is consistent with a
mechanism based on the partitioning of these drugs into the non-polar core of these
lipoproteins, as the order of these nKa values agrees with the fact that VLDL has a much
larger portion of hydrophobic components (i.e., cholesterol and triacylglycerides) than
either HDL or LDL [7,15,18,19].

CONCLUSIONS
The studies described in this chapter examined the extension and use of HPAC
with immobilized VLDL to examine the binding of drugs such as R- and S-propranolol to
this lipoprotein. The use of HPAC methodologies revealed that R- and S-propranolol had
a combination of two distinct types of interactions with VLDL. One of the interactions
was non-saturable in nature and probably involved the partitioning of propranolol into the
non-polar core of VLDL. This interaction is described by an overall affinity constant
ranging from 1.4-3.6  106 M-1 between 20 °C and 37 oC. The second interaction
identified during the HPAC studies was the result of site-specific, saturable binding. This
interaction is believed to occur between these drugs and apolipoproteins on the surface of
VLDL. The association equilibrium constants for these site-specific, saturable
interactions were in the range of 4.6-9.2  104 M-1 between 20 °C and 37 ºC.
The binding parameters determined in these studies with VLDL were in the
general range of those reported for propranolol when using a similar mixed-mode model
for immobilized HDL and LDL [10,26]. Previous studies utilizing soluble VLDL have
reported binding constants for racemic propranolol reported results based upon a non-
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saturable model, when the HPAC data presented in this chapter was examined using a
non-saturable model (see Table 4-2 and Table 4-3). The resulting overall affinities of
105-106 M-1 were consistently within the range that has been reported with soluble VLDL
[14]. The studies reported in this chapter also demonstrated that, despite the possible
presence of apolipoprotein B-100, VLDL does not exhibit stereoselectivity in propranolol
binding as was observed with LDL [10]. This difference is potentially due to the
difference in apolipoprotein content between VLDL and LDL. The lack of
stereoselectivity may also be related to changes in the accessibility and/or conformation
of apolipoprotein B-100 in the presence of other apolipoproteins in VLDL [29].
The suitability of HPAC as a technique to characterize mixed-mode binding
mechanisms between lipoproteins, such as VLDL, and drugs was again demonstrated in
these studies. As noted in work presented in Chapters 2 and 3, HPAC methodologies
provide a significant improvement over CE and equilibrium dialysis in terms of analysis
times [14,15]. In addition to the relatively short analysis times, HPAC columns
containing VLDL were sufficiently stable to be used for a large number of experiments.
In combination, these features enable the ability to achieve a significant reduction in the
amount of ligand needed for a large number of experiments when using HPAC
methodologies in lieu of equilibrium dialysis or CE studies.
The ability to use the same VLDL column for multiple studies eliminated or
minimized variations due to batch-to-batch changes in the binding agent preparations. In
addition, the use of the VLDL columns with standard HPLC equipment and detectors
provided good limits of detection and relatively high precision in the chromatographic
results [3,4,10,26]. These advantages make the reliable acquisition of data over a variety
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of drug concentrations possible. In turn, these features make it possible to compare
several binding mechanisms and enabled the identification of mixed-mode interactions
between VLDL and R- or S-propranolol. These features make similar HPAC columns
and methods a viable tool in future studies aimed at examining the binding of additional
drugs and solutes with VLDL or with other complex binding agents.
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CHAPTER FIVE
EVALUATION OF MIXED-MODE INTERACTIONS BETWEEN DRUGS AND
LIPOPROTEINS BY HIGH-PERFORMANCE AFFINITY
CHROMATOGRAPHY

INTRODUCTION
Frontal analysis high performance affinity chromatography (HPAC) was used
throughout this dissertation to evaluate the properties of lipoprotein columns, as
described in Chapter 1. These methods have been used to evaluate many binding agents
that contain a single type of interaction for an analyte [1-3] and to identify mixed-mode
interactions between several model drugs and HDL, LDL, or VLDL as cited previously.
These mixed-mode interactions are the result of the complex structure of lipoproteins,
which can give rise to both high-affinity binding at saturable sites and non-saturable
interactions with the lipoprotein core.
The goal of this study was to examine methods for detecting mixed-mode binding
of biological interactions and when using frontal analysis and HPAC. An emphasis was
placed on the evaluation of double-reciprocal plots for data analysis, though the use of
traditional binding isotherms was also evaluated. The binding of R-propranolol by LDL
served as a model system to illustrate such an analysis. This same model system was
examined in Chapter 3 and was shown to undergo mixed-mode interactions that
involved binding by R-propranolol by a group of high-affinity, saturable sites and a nonsaturable interaction. The ability of double-reciprocal plots to detect mixed-mode
binding was examined by using chromatographic theory. The expected result of these
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studies was that an improved method for the identification and study of mixed-mode
binding by frontal analysis HPAC would be determined. This method is expected to be
applicable to other systems that may involve in mixed-mode interactions.

THEORY
Frontal analysis data for a system containing a single group of saturable sites may be
analyzed by using the adsorption isotherm that is shown in Eq. (1) Alternatively, these
data can be analyzed by using the double-reciprocal form of the same isotherm, as shown
in Eq. (2) [3-4].

𝑚𝐿𝑎𝑝𝑝 =
1
𝑚𝐿𝑎𝑝𝑝

=

𝑚𝐿𝑡𝑜𝑡 𝐾𝑎1 [D]
(1+𝐾𝑎1 [D])
1
(𝐾𝑎1 𝑚𝐿𝑡𝑜𝑡

+
[D])

(1)
1
𝑚𝐿𝑡𝑜𝑡

(2)

Likewise, frontal analysis data for a system containing only a non-saturable interaction
may be analyzed by using the isotherm shown in Eq. (3) below, or via the doublereciprocal -form that is displayed in Eq. (4) [5-7].

𝑚𝐿𝑎𝑝𝑝 = 𝑚𝐿1 𝐾𝑎1 [D]
1
𝑚𝐿𝑎𝑝𝑝

=

1
(𝑚𝐿1 𝐾𝑎1 [D])

(3)
(4)

In these equations, mLapp is the apparent moles of analyte that are required to reach the
mean breakthrough point in a frontal analysis isotherm at a drug concentration of [D].
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The term mLtot is the total binding capacity (in moles) of the column for the applied drug
or target. The association equilibrium constant for the drug’s interactions with the
immobilized binding agent is represented by the term Ka1. Plotting the frontal analysis
data according to the expressions that are presented in Eqs. (1) and (3) is expected to
yield a linear response when non-saturable interactions are present and a non-linear
response if a single saturable group of binding sites is present. The difference in response
between these models makes distinguishing them relatively easy when evaluating the
binding isotherms.
A double-reciprocal plot of either the non-saturable model or a model for a single
group of saturable sites, as represented by Eqs. (2) and (4), is expected to yield a linear
response, although for non-saturable model an intercept of zero is obtained while a nonzero intercept appears in a saturable binding model. If deviations from linearity occur at
high analyte concentrations (i.e., at low values of 1/[D]), more than one type of
interaction must be present for the drug or target analyte [4,8].
Equations similar to these have been previously reported to describe the results in
frontal analysis experiments for systems that have two saturable groups of binding sites
[4,8]. The mathematical description of this latter binding model is shown in Eq. (5). The
double-reciprocal plot for this type of system is described by Eq. (6) [4,8].

𝑚𝐿𝑎𝑝𝑝 =
1
𝑚𝐿𝑎𝑝𝑝

=

𝑚𝐿1 𝐾𝑎1 [D]
𝑚 𝐾 [D]
+ (1+𝐿2𝐾 𝑎2[D])
(1+ 𝐾𝑎1 [D])
𝑎2
2 [D]2
1+ 𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1
2 [D]2 }
𝑚𝐿𝑡𝑜𝑡 {(𝛼1 + 𝛽2 − 𝛼1 𝛽2 )𝐾𝑎1 [D]+𝛽2 𝐾𝑎1

(5)
(6)
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In these equations, Ka1 is the association equilibrium constant for the drug or target
analyte at the binding site with the highest affinity (L1), and Ka2 is the association
equilibrium constant for the drug or target analyte at its binding site with the lower
affinity (L2). The values of mL1 and mL2 (or mL1,tot and mL2,tot) are the moles of these
saturable affinity binding sites. The term β is a dimensionless parameter that is defined
as the ratio of the association equilibrium constant for a specific site versus the highest
affinity site in the population (e.g., β2 = Ka2/Ka1, where 0 < Ka2 < Ka1; and β1 = Ka1/Ka1 =
1.00). The term α is also a dimensionless parameter and corresponds to the mole fraction
of all the binding regions that make up a given group of sites (e.g., for a two-site
saturable system, α1 = mL1/mLtot and α2 = mL2/mL,tot, where 1 = α1 + α2) [4,8].
Interactions between drugs and lipoproteins have been shown in the previous
chapters of this dissertation to follow mixed-mode binding in many situations. The
equation describing this binding model is shown in Eq. (7). This equation can be
rewritten in terms of Ka1 by using the parameter β2, where β2 is now equal to the term
n2Ka2/Ka1, and n2Ka2 represents the overall affinity for the non-saturable interaction. This
modified version of Eq. (7) is given in Eq. (8). The double-reciprocal form for this
equation is provided in Eq. (9).

𝑚𝐿𝑎𝑝𝑝 =

𝑚𝐿1 𝐾𝑎1 [D]
1+ 𝐾𝑎1 [D]

+ 𝑚𝐿2 𝐾𝑎2 [D]

(7)

𝑚𝐿𝑎𝑝𝑝 =

𝑚𝐿1 𝐾𝑎1 [D]
1+ 𝐾𝑎1 [D]

+ 𝛽2 𝐾𝑎1 [D]

(8)

1
𝑚𝐿𝑎𝑝𝑝

=

1+ 𝐾𝑎1 [D]
2 [D]2 )
[𝐷]+
𝑚𝐿𝑡𝑜𝑡 (𝐾𝑎1
𝛽2 𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1

(9)
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A double-reciprocal plot of 1/mLapp versus 1/[D], as made according to Eq. (6) or
(9), is expected to be non-linear across a broad range of analyte concentrations.
However, previous reports have demonstrated that these plots approach linear behavior at
low analyte concentrations for a two-site system [4,8]. This phenomenon also holds true
for a mixed-mode system, as shown by Eq. (10).

lim[D]→0 𝑚

1

𝐿𝑎𝑝𝑝

=

1
𝑚𝐿𝑡𝑜𝑡 (𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1 [D])

+𝑚

1

𝐿𝑡𝑜𝑡 (1+𝛽2 )

(10)

In this study Eqs. (9) and (10) were modified to the forms given in Eqs. (11) and
(12) and used in the examination of the effects of mixed-mode binding in frontal analysis.

𝑚𝐿𝑡𝑜𝑡
𝑚𝐿𝑎𝑝𝑝

=

1+ 𝐾𝑎1 [D]

(11)

2 [D]2 )
(𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1

𝑚

lim[D]→0 𝑚 𝐿𝑡𝑜𝑡 =
𝐿𝑎𝑝𝑝

1
(𝐾𝑎1 [D]+ 𝛽2 𝐾𝑎1 [D])

1

+ (1+𝛽

2)

(12)

All terms in Eqs. (11) and (12) are now expressed through the use of dimensionless
parameters. These parameters include the term β2, which was discussed previously, and
also include the combined term 1/(Ka1[D]) (i.e., the independent variable in a
dimensionless double-reciprocal plot) and the ratio mLtot/mLapp (i.e., the dependent
variable in a dimensionless double-reciprocal plot). These terms and equations were used
in this chapter to create universal plots to describe the effects of mixed-mode interactions
across a broad range of experimental conditions. A summary of the equations used to
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describe double-reciprocal plots of each binding model considered are shown in Table 51.

EXPERIMENTAL
Reagents
Individual enantiomers of R- and S-propranolol and the human LDL (catalog
number L7914, lot no. 036K1143), were purchased from Sigma (St. Louis, MO, USA).
Nucleosil Si-500 silica (7 µm particle diameter, 500 Å pore size) was procured from
Macherey Nagel (Düren, Germany). All other chemicals and reagents were of the
highest grades available. Reagents for the bicinchoninic acid (BCA) protein assay were
from Pierce (Rockford, IL, USA). Water dispensed from a Nanopure purification system
(Barnstead, Dubuque, IA, USA) and filtered using Osmonics 0.22 µm nylon filters from
Fisher Scientific (Pittsburgh, PA, USA) was used to prepare all solutions.

Apparatus
Frontal analysis studies were performed using a high performance liquid
chromatographic system comprised of two 510 HPLC pumps (Waters, Milford, MA,
USA), an F60-AL injection valve (Vici, Houston, TX, USA), a CH-500 column heater
(Eppendorf, Hauppauge, NY, USA) and a Waters 2487 UV/Vis variable wavelength
absorbance detector. Chromatograms were collected using Waters Empower software
and processed by programs based on Labview 5.1 (National Instruments, Austin, TX,
USA). Supports were placed into HPLC columns by using a slurry packer from Alltech
(Deerfield, IL, USA).

Table 5-1.

Summary of double-reciprocal expressions for binding models used with frontal analysis data for drugs on
lipoprotein columns

Predicted responsea
1/mLapp = 1/(mLtotKa1[D])
(7)
1/mLapp = 1/(mLtotKa1[D]) + (1/mLtot)
(8)
2
2
1/mLapp = (1+Ka1[D])/(mLtot(Ka1[D] + β2Ka1[D]+β2Ka1 [D] ))
(9)
1/mLapp = (1+Ka1[D]+β2Ka1[D]+β2Ka12[D]2)/(mLtot (α1+β2- α1β2) Ka1[D]+ β2Ka12[D]2)
where: α1 = mL1/mLtot
(10)
β2 = Ka2/Ka1
a
Symbols: mLapp, moles of applied analyte required to reach the mean position of the breakthrough curve; mL1, total moles of active binding site
Binding model
Non-saturable interaction
Single group of saturable sites
Saturable sites + non-saturable interaction
Two groups of saturable sites

1; Ka1, association equilibrium constant for binding of the analyte to the ligand at site 1; [D], concentration of the applied drug; mL2, total
moles of active binding site 2; Ka2, association equilibrium constant for binding of the analyte to the ligand at site 2.
Adapted from Refs. [7].
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Chromatographic studies
The LDL support was prepared as described in Chapter 3 and using the Schiff
base immobilization technique with Nucleosil Si-500 silica. A BCA protein assay was
conducted to determine the protein content of the support; this experiment revealed that
the LDL support contained 6.9 (± 0.4) mg protein per gram silica. The protein content
was used to determine the LDL content based on an average molar mass of 2.3  106
g/mol for LDL and a typical apolipoprotein content of 25% for LDL particles [6]. This
conversion indicated that 27.7 (± 1.6) mg or 12 (± 1) nmol of LDL per gram silica was
present (see Chapter 3). Diol silica was used as a control support in this study. The
LDL columns had previously been shown to be stable over the amount of time required
to collect the data required in this study, with no significant changes in the binding
properties of the column during these experiments (see Chapter 3).
Chromatographic data were collected using the HPAC system described earlier.
The LDL and control columns were stored in pH 7.4, 0.067 M phosphate buffer at 4°C
and equilibrated to 37 ºC prior to use. All mobile phases were filtered through Osmonics
0.22 µm nylon filters and degassed under vacuum prior to use. A wavelength of 225 nm
was utilized to monitor the elution of R- or S-propranolol in the frontal analysis studies.
These studies were performed in triplicate using 100 mm  2.1 mm i.d. columns packed
with the LDL support or control support and using a mobile phase of pH 7.4, 0.067 M
potassium phosphate buffer that was applied at a flow rate of 1.0 mL/min at 37 ºC.
Nine solutions containing R- or S-propranolol, with concentrations ranging from
0.2-25 µM in the pH 7.4, 0.067 M potassium phosphate buffer, were applied to the LDL
and control columns during the frontal analysis studies. This range was selected as 0.2
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µM was approximately equivalent to the lowest concentration at which breakthrough
times for R- and S-propranolol could be reliably determined, and 25 µM provided a
response within the linear range of the detector and overlapped with drug concentrations
that have been used in prior CE/frontal analysis studies [9]. Following the frontal
analysis measurements, the retained drug was eluted by passing pH 7.4, 0.067 M
potassium phosphate buffer through the column prior to the next experiment.
At the conclusion of frontal analysis experiments, the moles of applied drug
needed to reach the mean point of each breakthrough curve was determined by
integration of this curve by using a program based on Labview software [10].
Corrections were made for the void time and non-specific binding of the drug to the LDL
support by subtracting the breakthrough time obtained using the control support from the
time measured for the same drug on the LDL support at each concentration of drug that
was examined.
Linear regression was performed with Excel 2010 (Microsoft, Redmond, WA,
USA). Nonlinear regression was executed using Origin 9.1 software (OriginLab,
Northampton, MS, USA). Surface plots and contour plots were prepared using Origin
9.1.

RESULTS AND DISCUSSION
Evaluation of binding isotherms and double-reciprocal plots
Evaluation of drug-lipoprotein binding throughout this dissertation has usually fit
a model with two types of interactions.. The interactions between these drugs and
lipoproteins are described by a model in which high affinity, saturable interactions occur
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between the drug and apolipoproteins, and a second non-saturable interaction occurs
between the drug and the non-polar core of the lipoprotein. This was confirmed by
evaluating R-propranolol interactions with LDL. As reported in Chapter 3, this system
had a single saturable, high affinity site with a Ka1 of 5.2 (± 2.3) × 105 and a nonsaturable interaction with an overall affinity of 1.9 (± 0.1) × 105 at 37 ºC. The
interactions of propranolol with LDL were stereoselective, and the interactions between
S-propranolol and LDL followed a non-saturable interaction model between the drug and
non-polar core of LDL.. The overall affinity of this interaction was determined to be 2.7
(± 0.2) × 105 at 37 ºC.
The effect that these mixed-mode interactions have on the use of traditional
binding isotherms is demonstrated by Figure 5-1. As shown by this figure (and in
Chapter 3), the binding of R-propranolol to LDL gives reasonable agreement with the
non-saturable, one-site saturable, and mixed-mode models across the concentration range
that was evaluated. The goodness of fit exhibited for each of these binding models may
make it difficult to distinguish between these models, particularly if a narrower
concentration range were used during the experiments. This demonstrates that
determining association equilibrium binding constants and number of binding sites
through this method requires a suitable number of data points that span a broad range of
concentrations to accurately assess the number and type of interactions that may be
present.
An alternate approach utilizing double-reciprocal plots for the initial detection of
multiple types of interactions has been proposed in previous work with other systems
[11-13] and was utilized in previous chapters of this dissertation. Based upon the
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equations given in Table 5-1, the double-reciprocal plot of a non-saturable or one-site
saturable binding model should yield a linear response. The two-site saturable and
mixed-mode models should approach a linear relationship at low analyte concentrations
(or high values of 1/[D]). At high analyte concentrations (or low values of 1/[D]), these
second two models predict that deviations from a linear response will occur. The
presence of these types of deviations can be used to assess whether a system exhibits
single or multiple types of interactions [4,11-13]. An example of a double-reciprocal plot
is shown in Figure 5-2; this plot was prepared using the same data for R-propranolol/LDL
interactions as were used in Figure 5-1. This plot shows that at low concentrations of Rpropranolol (i.e., high concentrations of 1/[D]), a linear range is present as predicted. In
addition, lower values of 1/[D] show negative deviations from the linear range, indicating
that multiple types of interactions were present between R-propranolol and LDL.
Additional examples of double-reciprocal plots are shown in Chapters 2, 3, and 4.
Further evaluation of Figures 5-1 and 5-2 reveals the primary advantage of using
double-reciprocal plots to examine frontal analysis data for multiple types of interactions.
This advantage lies in the fact that significantly less data are required to detect multiple
interactions, which occurred for interactions between R- or S-propranolol and HDL, LDL,
or VLDL, as well as between R/S-verapamil and HDL. For example, the studies with Rpropranolol and LDL presented in Figure 5-1 required nine measurements in the drug
concentration range of 0.2 to 25 µM to differentiate between the four binding models
presented in Table 5-1 (i.e., the non-saturable interaction, single group of saturable sites,
mixed-mode with single group of saturable sites and non-saturable interactions, and two
groups of saturable sites). When analyzing the double-reciprocal plot, the three highest
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values of 1/[D] agreed with the best fit line within ± 4%, however, the next four highest
values of 1/[D] deviated from this line by 30.8%, 35.1%, 46.9%, and 53.2%, respectively.
These deviations are significantly larger than the typical experimental precision of ± 45% that reported in Chapter 3 for the LDL studies.. Given these levels of deviation, data
from as few as five concentrations spanning the concentration range of 1 to 10 µM could
have been used to detect mixed-mode interactions when using a double-reciprocal plot.
This observation supports the prior results in Ref. [4] that the use of a double-reciprocal
plot instead of a normal binding isotherm requires fewer experiments and a significantly
smaller amount of drug for the detection of binding site heterogeneity in systems with
multiple types of saturable interactions.
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Figure 5-1.

Frontal analysis data for the binding of R-propranolol to LDL, as
examined according to binding isotherms described by the non-saturable
(red dashed line), one-site saturable (blue dashed line), and mixed-mode
binding models (solid line).
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Figure 5-2.

Frontal analysis data for the binding of R-propranolol to LDL, as
examined using a double-reciprocal plot. The best fit line was obtained
using data points in the upper region of this plot, which are designated by
the closed squares (■). Data points in the lower region of this plot (i.e., at
higher concentrations propranolol) showed negative deviations from the
linear fit for R-propranolol and are represented by open squares (□).
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Conditions leading to deviations from linearity in mixed-mode plots
The ability of double-reciprocal plots to detect binding heterogeneity in a two-site
system has been previously examined, but no work to date has extended this approach to
the evaluation of a mixed-mode system containing a saturable group of binding sites and
a non-saturable group of sites [4]. The work presented here examined the degree of
deviations from linearity in double-reciprocal plots that are obtained for systems with
varying degrees of impact from the two interaction modes. Examination of Eq. (12)
reveals that two system constants can be varied to evaluate the impact and magnitude of a
deviation from linearity in this type of system (β2 and Ka1). The impact of varying these
parameters was evaluated by determining the relative deviation from linearity, as
described in Eq. (13).

% Deviation=

Eq. (12)-Eq. (11)
Eq. (12)

×100%

(13)

This equation was used to determine the difference between the actual response of a
double-reciprocal plot (as predicted by Eq. 11) and the response of the linear region (as
predicted by Eq. 12); the difference in this response was subsequently converted to a
percentage by dividing by the linear response and multiplying by 100%. The use of Eq.
(13) in this approach produced a mechanism by which the relative deviation from
linearity could be predicted when varying the values of β2 and 1/(Ka1[D]) for any mixedmode system.
The first evaluation performed by this method was to determine the relative
deviation from a linear response when the value of 1/(Ka1[D]) was varied between 0.05
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and 0.50. Figure 5-3 shows that the greatest deviations from a linear response occurred
when small values of 1/(Ka1[D]) were present. The impact of the relative deviations
increased as the value of β2 increased. These results are aligned with the data presented
in Figure 5-2, where the deviations from linearity increased as the value of 1/(Ka1[D])
decreased. The relative deviation from a linear response when the value of β2 was varied
was also determined between 0.2 and 10.0. Figure 5-4 confirmed that the largest
deviations from a linear response occurred when β2 was large and 1/(Ka1[D]) was small.
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Figure 5-3.

Percent deviation from a linear response in the value of mLtot/mLapp for a
double-reciprocal frontal analysis plot for a mixed-mode system in which
1/(Ka1[D]) = 0.05, 0.10, 0.20, or 0.50 as a function of the ratio of the total
affinity of non-saturable sites versus the affinity of saturable sites.
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Figure 5-4.

Percent deviation from a linear response in the value of mLtot/mLapp for a
double-reciprocal frontal analysis plot for a mixed-mode system in which
β2 = 0.20, 0.365, 1.0 and 10.0 as a function of the value of 1/Ka1. The β2
value was selected as the approximate value obtained for nKa/Ka1 in
frontal analysis studies between R-propranolol and LDL at 37 ºC (refer to
Chapter 3).
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The impact that simultaneous variations in the values of β2 and 1/(Ka1[D]) have on
the relative deviation from linearity was evaluated using surface and contour plots. These
plots are shown in Figures 5-5 and 5-6. The plot trends agree with those noted in Figures
5-3 and 5-4, in which the relative deviations from a linear response increased as the value
of β2 increased or 1/(Ka1[D]) decreased. This also fits the experimental data presented in
Figure 5-2.
These results are logical when considered in conjunction with the models
presented above. A decreasing value of β2 represents a decrease in the value of
n2Ka2/Ka1. This is indicative of a diminished portion of non-saturable binding relative to
site-specific, saturable binding. As the value of n2Ka2/Ka1 begins to approach zero, the
mixed-mode model begins to reflect the one-site saturable model, which has a linear
double-reciprocal plot. Similarly, an increase in the value 1/(Ka1[D]) reflects a decrease
in the association equilibrium constant Ka1 or the value of [D]. As the value of Ka1 or [D]
approaches zero, the mixed-mode binding model begins to reflect the non-saturable
model. The double-reciprocal plot for non-saturable binding is depicted by a linear
relationship.
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Figure 5-5.

Surface plot showing the relative deviation from a linear response in the
value of mLtot/mLapp for a double-reciprocal frontal analysis plot for a
mixed-mode system.
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Figure 5-6.

Contour plot showing the relative deviation from a linear response in the
value of mLtot/mLapp for a double-reciprocal frontal analysis plot for a
mixed-mode system.
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CONCLUSIONS
The work in this chapter evaluated the use of data collected from HPAC-frontal
analysis studies to detect mixed-mode binding of analytes in biological systems such as
drug-lipoprotein interactions. The use of double-reciprocal plots in the detection of
mixed-mode binding was emphasized. Theoretical evaluations were conducted to
determine the effects mixed-mode binding would have on double-reciprocal plots and to
predict the extent of deviations from linearity that would be expected in these plots for
various mixed-mode systems. Frontal analysis experiments analyzing the interactions
between R-propranolol and LDL were used to provide double-reciprocal plots and to
access if such plots could simplify the detection of mixed-mode binding when compared
to traditional binding isotherms. Examination of this system also demonstrated that
double-reciprocal plots can be used to identify mixed-mode binding with fewer
measurements, and therefore less target analyte, than would be required when utilizing
traditional binding isotherms. Therefore, double-reciprocal plots are an attractive
alternative for screening systems for mixed-mode interactions.
This report also demonstrated that the relative deviations that result from mixedmode interactions are predictable. The deviations from linearity observed in a doublereciprocal plot for a mixed-mode interaction are a function of the applied drug’s
concentration, the relative affinity of the saturable binding site, and the overall affinity of
the non-saturable interaction. The results of this study showed that as the relative affinity
of the saturable binding (as represented by Ka1) or the applied drug’s concentration
decreased, so did the deviations from a linear response. This is due to the fact that as the
value of Ka1 or [D] approaches zero, the mixed-mode binding model begins to reflect the
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non-saturable model. This study also demonstrated that as the overall affinity of the nonsaturable interaction (as represented by β2) decreased the mixed-mode model began to
reflect the one-site saturable model and deviations from linearity were reduced. These
findings should be applicable to any mixed-mode binding system and are not limited to
the evaluation of drug interactions with lipoproteins.
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CHAPTER SIX
SUMMARY AND FUTURE WORK

SUMMARY OF WORK
The work in this dissertation examined the interactions of drug with lipoproteins,
where lipoproteins are soluble macromolecular complexes of proteins and lipids that are
present in the serum to transport hydrophobic compounds, such as cholesterols and
triglycerides [1-3]. As was shown in the previous chapters, these complexes are able to
bind several basic and neutral hydrophobic drugs, including propranolol and verapamil
[4]. The reversible nature of the interactions between these drugs and lipoproteins
influences the activity, pharmacokinetics and toxicity of drugs in the human body and
impacts the distribution, delivery, metabolism, and excretion of these drugs [5-10]. This
dissertation evaluated the binding of propranolol and verapamil, to various lipoproteins.
These studies focused on the use of high-performance affinity chromatography (HPAC)
to evaluate the interactions between such drugs or solutes and lipoproteins.
The application of HPAC was first implemented in the Chapter 2 in studies
conducted with high density lipoprotein (HDL). Chromatographic columns containing
immobilized HDL were used in HPAC studies to examine interactions between HDL and
propranolol or verapamil. These columns were prepared by immobilizing HDL to
HPLC-grade silica by using the Schiff base method and placing the resulting support into
a column. The stability of these columns was confirmed for up to 120 h of continuous
operation in the presence of pH 7.4, 0.067 M potassium phosphate buffer and when they
were used in zonal elution studies. Following the establishment of this column stability,
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frontal analysis experiments were conducted to determine the type and strength of
interactions that occurred between the given drugs and HDL. It was determined that two
types of interactions occurred between HDL and propranolol or verapamil. The first type
of interaction had a relatively high affinity and was probably related to an interaction
between the drugs and apolipoproteins on the surface of HDL. The second type of
interaction fit a non-saturable binding model, as would be expected to occur in
interactions of these drugs with phospholipids or the non-polar core of HDL. The high
affinity sites had association constants of 1.1-1.9 × 105 M-1 for R- or S-propranolol and
6.0 × 104 M-1 for R/S-verapamil at 37 ºC. The overall affinity (nKa) for the weaker
interactions at 37 oC was estimated to be 3.7-4.1  104 M-1 for R- or S-propranolol and 2.5
 104 M-1 for R/S-verapamil at 37 oC. The non-saturable interaction constants that were
obtained for each drug were in close agreement with the results of previous solutionphase studies [11-13].
The use of HPAC in the analysis of lipoprotein-drug interactions was extended to
low density lipoprotein (LDL) in Chapter 3. HPAC columns containing immobilized
LDL were again prepared via the Schiff base reaction. These columns were used to
analyze the nature and strength of R- and S-Propranolol interactions with LDL. Frontal
analysis experiments indicated that two types of interactions occurred between Rpropranolol and LDL, while only a single type of interaction resulted between Spropranolol and LDL. The interactions for both enantiomers involved non-saturable
binding; this interaction had an overall affinity (nKa) of 1.9 (± 0.1)  105 M-1 for Rpropranolol and 2.7 (± 0.2)  105 M-1 for S-propranolol at 37 ºC. The second type of
interaction was targeted only R-propranolol and involved saturable binding that had an
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association equilibrium constant (Ka) of 5.2 (+ 2.3)  105 M-1 at 37 ºC. Differences in
binding behavior were similar for the two enantiomers at 20 ºC and 27 ºC. These results
were approximately the same as the overall affinities that have been measured for the
same drugs with soluble LDL and based on a non-saturable model [10,14]. These results
also represented the first known report and example of stereoselective binding by drugs
to LDL or other lipoproteins.
Chapter 4 described the use of HPAC to examine the binding of very low density
lipoprotein (VLDL) with drugs, using R- and S-propranolol as model solutes. These
studies identified the existence of two binding mechanisms between R- and S-propranolol
and VLDL. The first mechanism involved non-saturable partitioning of these drugs with
VLDL. This partition-type interaction was described by overall affinity constants of 1.2
(± 0.3)  106 M-1 for R-propranolol and 2.4 (± 0.6)  106 M-1 for S-propranolol at pH 7.4
and 37 ºC. The second mechanism occurred through saturable binding by these drugs at
fixed sites, such as apolipoproteins on the surface of VLDL. The association equilibrium
constants for this saturable binding at 37 ºC were 7.0 (± 2.3)  104 M-1 for R-propranolol
and 9.6 (± 2.2)  104 M-1 for S-propranolol. Comparable results were obtained at 20 ºC
and 27 ºC for the propranolol enantiomers. No stereoselectivity was observed in the
binding of R- or S-propranolol with VLDL.
The results obtained in Chapters 2, 3, and 4 also demonstrate the suitability of
using immobilized lipoproteins and HPAC to study the interactions that occur between
lipoprotein and drugs or other analytes. When compared with equilibrium dialysis (i.e.,
the method used in Ref. [11] and a common reference method for drug binding studies),
HPAC has several benefits, including analysis times of only a few minutes per run and
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use of the same lipoprotein ligand for many experiments. An alternative method based
on capillary electrophoresis (CE) has been applied to drug binding studies with
lipoproteins [12-14]. This CE method requires less protein than HPAC for a single
analysis; however, the ability to reuse HPAC columns that contain immobilized
lipoproteins results in a method that needs a similar or smaller amount of ligand than CE
when dealing with a large number of samples or studies. Furthermore, the ability to use
the same lipoprotein preparation for multiple studies helped reduce the effects of batchto-batch variability in the ligand in the HPAC method. The ability to utilize HPLC
detectors with such columns allowed the examination of a relatively wide range of low
and high drug concentrations possible in the HPAC approach and enabled the
identification of high affinity interactions located on HDL, LDL, and VLDL. The same
interactions were not observed in previous studies using CE or equilibrium dialysis [1114].
The work performed in Chapter 5 examined the theory and experimental
conditions needed for the detection of multiple binding mechanisms in HPAC columns
when using frontal analysis. This work focused on evaluating binding models that
incorporated both a saturable type of binding and a non-saturable interaction. These
evaluations made it possible to determine the experimental conditions that would be
required for detection of this type of multi-mode interaction.
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FUTURE WORK
Analysis of oxidized lipoproteins
The results presented throughout this dissertation have demonstrated that the
HPAC is an effective method for examining interactions between solutes and various
lipoproteins (i.e. HDL, LDL, and VLDL). This method has the ability to identify
multiple types of binding or interactions that are not typically observed in studies based
upon equilibrium dialysis or CE. HPAC also enabled the identification of stereoselective
interactions between lipoproteins and solutes. Based upon this ability of HPAC to obtain
additional information regarding interactions with lipoproteins, further studies involving
the application of HPAC in the examination of lipoprotein binding is logical. The
examination of the effects of lipoprotein oxidation on drug binding is one area that merits
further research.
Plasma LDL has been shown to undergo in vivo chemical modification, such as
oxidation and acetylation by endothelial cells, arterial smooth muscle cells, macrophages,
and lymphocytes [15]. These modifications impact both the protein and lipid
components of LDL and are often associated with atherosclerosis [16]. Furthermore,
previous studies have shown that this process can impact the uptake of LDL and the
binding affinity of drugs to this lipoprotein [13-15]. The impact of LDL oxidation on
binding by the drugs verapamil and nilvadipine has been studied via methods based upon
CE [13-15]. These studies showed that the total affinity of each drug increased upon
LDL oxidation. The degree to which each drug is impacted varied, with the basic drug
verapamil being impacted more than the neutral drug nilvadipine [13-15].
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Despite the reported results, it is logical that the use of CE would suffer from the
same drawbacks as reported in Chapters 2, 3, and 4. The use of HPAC methods in
studying the interactions of oxidized LDL with drugs would be expected to yield
additional information regarding the nature and strength of these interactions. The
realization of such additional information is expected to arise from the use of the binding
models presented in Table 1-2 that consider multiple interactions. Furthermore, the
ability to use utilize HPLC detectors in these studies should allow for the examination of
a wider range of low and high drug concentrations that was used in the studies with CE,
thus enabling the identification and assessment of the impact of oxidation on more types
of interactions.
The execution of drug binding studies using oxidized LDL (or other lipoproteins)
via HPAC would employ similar methods to those described in Chapters 2, 3, and 4.
The first step in this evaluation would be the oxidation of the lipoprotein. Previous
methods have described a process by which Cu2+ can induce the oxidation of LDL [17].
This oxidation would be carried out by placing a preparation of this lipoprotein in pH
7.4, 0.067 M phosphate buffer containing 5 µM CuSO4, with this mixture then being
incubated at 37 ºC for 0.5 to 12 h to obtain various levels of oxidation. The reaction
could be terminated using ultrafiltration to remove the CuSO4. The oxidation state of
LDL could be monitored by using three separate methods, as reported previously [15].
The simplest method would be to monitor the UV absorption at 234 nm. Oxidation of
LDL results in conjugated diene structures in unsaturated acyl chains, and the formation
of these structures results in an increase in UV absorption. Alternatively, the oxidation
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state of LDL may be monitored via fluorescence or the electrophoretic mobility of LDL
versus oxidized LDL [15].
Following the oxidation of LDL, this lipoprotein could be immobilized and placed
in a chromatographic column for use in HPAC studies. This immobilization to HPLC
grade silica would be accomplished using the Schiff base reactions described in
Chapters 2, 3, and 4. Oxidation of LDL does have the potential to diminish or alter the
immobilization efficiency due to the formation of Schiff bases between the ε-amino
groups of lysine residues on the apolipoproteins and aldehyde group formed by
degradation of the unsaturated acyl chains in the lipids of LDL [15]. In the event that the
immobilization efficiency is diminished to the point that the Schiff base method is not
viable, alternative immobilization techniques may be used. Entrapment would be an
alternative immobilization technique that is likely to be successful. Entrapment of LDL
would occur by placing the lipoprotein within the pores of dihydrazide-activated silica
and then capping the pores with oxidized glycogen, as has recently been used for the
immobilization of some serum proteins [18]. The support containing oxidized LDL
would then be packed within chromatographic columns and employed in HPAC studies
using zonal elution or frontal analysis.
The stability of the oxidized LDL supports would be assessed using zonal elution,
as described in previous lipoprotein studies (see Chapters 2, 3, and 4). Following
determination of the column’s usable lifetime, frontal analysis would be initiated.
Analysis of the breakthrough times obtained from frontal analysis, and using doublereciprocal plots or non-linear regression, will be carried out according to binding models
based upon non-saturable interactions, one group of saturable sites, two groups of
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saturable sites, and the mixed mode model (i.e., one group of saturable sites plus a nonsaturable interaction), as described in Table 1-2. Analysis using these binding models
should provide information regarding the impact oxidation has on the ability of
apolipoprotein B-100 to selectively bind R-propranolol. The impact that the oxidation of
lipids has on the partitioning of propranolol into the non-polar core of LDL should also
be revealed through these experiments.

Analysis of glycated lipoproteins
In vivo oxidation has been long studied as an atherogenic modification of
lipoproteins that impacts the function of these agents [16,17,19]. Recently, there has also
been an increasing interest in the role that glycation plays in the impairment of
lipoprotein function [19]. This interest has arisen from a failure of antioxidant therapy to
reduce the occurrence of atherogenic cardiovascular diseases in high-risk individuals
[19]. Glycation is a non-enzymatic reaction that proceeds via formation of a Schiff base;
the product of this reaction may undergo an Amadori rearrangement and form a stable
ketoamine link with exposed lysine residues of the apolipoprotein to produce an early
glycation product [19]. Glycation may be induced by reactive sugars (e.g., glucose) and
may impact each class of lipoproteins [19]. Glycated lipoproteins are present in the
circulation under physiological conditions and are present at high concentrations in
individuals with diabetes or other conditions [19]. The prominence of glycated
lipoproteins in vivo and the impact that disease states such as diabetes have on their
formation makes the study of interactions between glycated lipoproteins and drugs or
other solutes of interest.
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The glycated lipoprotein that has been the most studies is LDL [19]. Therefore,
this glycated lipoprotein will be the first analyzed in drug binding studies by HPAC.
These studies will involve a further adaptation of the methodologies that were described
previously in this dissertation. As with drug binding studies involving oxidized LDL, the
success of this method will depend on the ability to produce and immobilize glycated
LDL. A number of in vitro methods for the generation of glycated LDL (and other
lipoproteins) have been reported previously, these can be seen in Table 6-1.
Commercially available LDL will be glycated according to one of these methods.
Following glycation, the modified LDL will be immobilized and placed in a
chromatographic column for use in HPAC. This immobilization to HPLC grade silica
could be accomplished by using the Schiff base method, described in Chapters 2, 3, and
4 of this dissertation. As with oxidized LDL, the immobilization efficiency of glycated
LDL may be diminished to the point that the Schiff base method is not viable. If this
occurs, entrapment may be an effective alternative immobilization technique.
Entrapment of LDL would occur by placing the lipoprotein within the pores of
dihydrazide-activated silica and then capping the pores with oxidized glycogen [18].
HPAC studies using zonal elution and frontal analysis would then be employed to
evaluate the column stability and interactions between drugs (e.g., propranolol) and the
glycated LDL.

Table 6-1

a

In vitro conditions that have been used to synthesize glycated LDL [19]

Glycating agenta

Glycating agent

LDL (mg/mL)

Duration

Temperature

Other Factors

Glucose

80 mM

2.4 - 2.7

5 days

37 ºC

NaCNBH3 (200 mM); gas not specified

Glucose

25 mM

3

6 days

37 ºC

NaN3; EDTA; 5% (v/v) CO2, 95% (v/v) O2

Glucose

500 mM

0.25

28 days

37 ºC

Under air; EDTA; dark

GA, MG, or glucose

100 mM

0.35 – 30.45

14 days

37 ºC

5% (v/v) CO2; 95% (v/v) O2

Glucose

100 mM

0.5

6 days

37 ºC

N2 0.5 mM; EDTA

GA, MG, or glucose

100 mM

1

7 days

37 ºC

5% (v/v) CO2; 95% (v/v) O2

GA or MG

10 mM

1

7 days

37 ºC

5% (v/v) CO2; 95% (v/v) O2

Glucose

30-80 mM

1

7 days

37 ºC

N2; NaN3

Abbreviations: GA, glycoaldehyde; MG, methylglyoxyl.
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Zonal elution studies
The analysis of drug interactions with lipoproteins by HPAC in this dissertation
has revealed that HDL, LDL, and VLDL are all capable of multiple interactions with
drugs (see Chapters 2, 3, and 4). In addition to the non-saturable, partition type
interactions that have been identified through prior work [11-14], these current studies
have revealed that apolipoproteins on the surface of HDL, LDL, and VLDL are capable
of high affinity, site-specific interactions. These high-affinity, site-specific interactions
have not been identified previously when using equilibrium dialysis or CE methods and,
as a result, have not been the subject of further study. The study of these saturable
binding sites is a potential area for future study. The use of zonal elution and HPAC
could provide an effective mechanism for the study of these sites.
Zonal elution studies in HPAC were described in Chapter 1 and used in
conducting column stability studies throughout this dissertation. In this technique, a
narrow plug of the analyte is injected onto the affinity column under isocratic conditions
as a detector is used to monitor the elution time of the injected compound [20]. When the
kinetics of association and dissociation are fast relative to the time scale of the
experiment, the retention time of the analyte is directly related to its strength of binding
to the immobilized agent and the amount of binding agent that is present in the column
[18,20]. The conditions utilized in these experiments (e.g., pH, ionic strength,
temperature, type of target, type of affinity ligand, and presence of competing agents in
the mobile phase) may be altered to yield changes in the analyte retention [18,20].
Monitoring these changes as the conditions are varied can provide detailed data regarding
the nature of interactions between the analyte and immobilized binding agent [18,20].
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The frontal analysis experiments described in Chapter 2 revealed that both
verapamil and propranolol are capable of site-specific interactions with HDL. These
experiments allowed for the identification of this type of binding between the drugs and
HDL, but did not give specific information regarding the location of these binding sites
on HDL’s apolipoprotein. Execution of zonal elution experiments in which one of the
drugs is dissolved in the mobile phase as a competing agent at varying concentrations
would aid in determining if these compounds are competing for the same apolipoprotein
binding sites. A decrease in the retention of the injected analyte as the drug in the mobile
phase (i.e., pH 7.4, 0.067 M phosphate buffer) is increased would indicate whether direct
competition, no competition or allosteric effects are occurring between the two
compounds on HDL. In the event that the binding of propranolol and verapamil occur
independently (e.g., at different sites on the apolipoproteins), no change in the retention
of the injected analyte would be observed as the concentration of the drug in the mobile
phase is increased. Similar studies could be conducted with LDL and VLDL columns or
with additional drugs that have been found to undergo site-specific interactions with these
lipoproteins.
The frontal analysis experiments conducted in Chapter 3 revealed the presence of
stereoselective binding of R- and S-propranolol by LDL; this phenomena may also be the
subject of further study through zonal elution. The stereoselective nature of this
interaction may be evaluated by using multiple types of studies on columns prepared as
described in Chapter 3. One mechanism to confirm the stereoselectivity of this binding
would be to conduct a competition study, as described in the previous paragraph. In such
a study, S-propranolol could be dissolved in the mobile phase (i.e., pH 7.4, 0.067 M
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phosphate buffer) while R-propranolol is injected and monitored for its elution. As the
concentration of S-propranolol in the mobile phase is increased, the retention of Rpropranolol would be expected to remain constant. A constant retention time for Rpropranolol would indicate a lack of competition for saturable binding sites on the
apolipoprotein and confirm the stereoselective nature of this interaction. The
stereoselectivity of R- and S-propranolol binding by LDL could also be evaluated by
performing a chiral separation of the two compounds. In these studies, the two
enantiomers would be injected as racemic mixture in the zonal elution mode. A chiral
separation would be expected to yield a distinct peak for each enantiomer; this separation
would not be expected in a system that did not exhibit stereoselective binding.
Experimental conditions such as temperature, pH, ionic strength, and polarity may be
modified to increase the resolution between these enantiomers or to increase the speed of
this separation [20].
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